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The FADS1 and FADS2 genes encode fatty acid desaturases required for 
synthesis of omega-3 and omega-6 long-chain polyunsaturated fatty acids 
(LCPUFA) important in the central nervous system, inflammatory response, 
and cardiovascular health.  The adjacent FADS3 gene is a putative 
desaturase, and both FADS2 and FADS3 have alternative transcripts (AT) of 
unknown function.  Here, genetic, dietary and molecular factors regulating 
expression and alternative splicing of FADS genes were identified.  A FADS2  
haplotype was significantly associated with FADS1 expression in lymphoblasts 
from Japanese International HapMap participants, and overlapped with a 
predicted sterol response element (SRE).  Minor haplotype homozygotes had 
significantly higher induction of FADS1 and FADS2 after treatment with a 
statin drug or an LXR agonist, both activators of SREBP-1c.  Sequencing 
identified 2 deletions within 150 bp of the putative SRE only present in minor 
haplotype carriers, suggesting this region controls response to SREBP-1c.  
We next examined the effect of dietary LCPUFA levels on baboon liver FADS 
gene expression.  FADS1 and both FADS2 transcripts were downregulated by 
 dietary LCPUFA, but FADS3 AT were upregulated, both in baboon liver and 
human liver-derived HepG2 cells.  A PPARγ antagonist prevented FADS3 
upregulation, while FADS1 and FADS2 were unaffected.  In HepG2 cells, 
knockdown of the polypyrimidine tract binding protein (PTB) modulated 
alternative splicing of FADS2 and FADS3.  PTB and FADS2AT1 were 
inversely correlated in neonatal baboon tissues, implicating PTB as a major 
regulator of tissue-specific FADS2 splicing. Omega-3 fatty acids decreased by 
nearly one half relative to omega-6 fatty acids in PTB knockdown cells, with a 
particularly strong decrease in eicosapentaenoic acid concentration and its 
ratio with arachidonic acid.  The baboon results showing an opposing pattern 
and mechanism of regulation suggested a dissimilar function for FADS3 AT 
compared to classical desaturases, and PTB knockdown results suggested 
possible dominant negative inhibition by FADS splice variants. This is a rare 
demonstration of a mechanism specifically altering the cellular omega-3 to 
omega-6 fatty acid ratio without any change in diet/media.  These findings 
reveal how genotype and alternative splicing affect response to diet and 
medication, and alter availability of eicosanoid precursors for cell signaling.    
 
 
 iii 
BIOGRAPHICAL SKETCH 
Holly Turner Reardon grew up in North Hollywood, California.  She began 
attending the University of California, Los Angeles part-time at the age of 15, 
and continued there full-time after graduating as valedictorian of her class at 
North Hollywood High School.  She paid for college entirely with merit 
scholarships, including a National Merit Scholarship and a California Robert C. 
Byrd Scholarship.  During college she read an article about a biotechnology 
start-up company called Tularik (now part of Amgen), which was seeking to 
discover drugs targeting transcription factors (a novel idea in those days.)  
Intrigued, she wrote to the company and asked if she could work there for a 
summer; in response, the company created a summer internship for her and 
later hired her full-time.  She graduated magna cum laude from UCLA in 1995 
with a B.S. in Molecular, Cellular and Developmental Biology, and moved to 
the San Francisco bay area.  After Tularik, she worked in cancer drug 
discovery at Axys Pharmaceuticals (now part of Celera Genomics), and later 
developed microfluidic assays and instrumentation at Caliper Life Sciences.  
She was promoted six times in ten years, eventually reaching Ph.D.-level 
positions of Scientist I and Scientist II for her last four years in industry.  
Seeing the first signs of an economic downturn ahead, she began to worry 
about holding positions without the necessary credentials, and decided to go 
back to school for a Ph.D.  As a strong believer in the Japanese saying, “food 
is medicine,” she decided she would like to bring her pharmaceutical industry 
perspective to the study of bioactive components in food.  Eventually choosing 
the Molecular Nutrition program at Cornell, she became interested in omega-3 
fatty acids and entered the laboratory of J. Thomas Brenna.   
 iv 
 
 
 
 
 
 
 
 
For my late father, Frank Turner.   
He showed me which weeds in our yard were edible, how to tell the direction 
the Earth was moving by the path of stars in the sky, how to grow hydroponic 
strawberries on a smoggy rooftop, how to diagnose car trouble, and many 
other interesting things.  In short, he taught me to think like a scientist.  In his 
life, he was a counter-intelligence agent in World War II, a tractor operator, a 
mechanical engineer who designed jet engines, a mailman and later a postal 
supervisor, and a chemistry hobbyist who started his own company converting 
solid silver into a sprayable form.  But most of all, he was an amazing and 
inspiring parent.  I wish he were still here. 
 
 v 
ACKNOWLEDGMENTS 
 
I am tremendously grateful to my advisor, Tom Brenna, for giving me an 
amazing amount of freedom in choosing my research topics and designing my 
studies.  I am also very thankful for funding support in my 4th year through an 
NRSA training grant in Reproductive Sciences and Genomics (Grant Number 
T32HD052471), and I thank Cornell for funding me in my first year through a 
Presidential Life Sciences Fellowship.  I am indebted to the other members of 
the Brenna lab for creating a wonderful work environment.  In particular, I am 
especially grateful to Woo Jung Park and Kumar Kothapalli for teaching me to 
work with RNA and do PCR, and for many helpful talks and lots of teamwork.  
I was especially lucky to have Jimmy Zhang, a very talented undergraduate, to 
work with me in the lab.  Pete Lawrence was incredibly helpful with fatty acid 
analysis.  My office mate, Rinat Ran-Ressler, was great company and helped 
preserve my sanity.  Outside our lab, I am grateful to Magnolia Ariza-Nieto for 
helpful advice and gracious access to instruments. 
 
I could not have got through this graduate school adventure without my caring 
family and the support of my wonderful husband, Brian Reardon.  Also, kudos 
to my baby Helen for sleeping occasionally over the past five months so I 
could get some work done; heartfelt thanks to my mom for the glider, and to 
Lily and Paul Wallace for the baby swing, that helped to make the sleeping 
possible.  
 vi 
TABLE OF CONTENTS 
 
Biographical Sketch          iii 
Dedication           iv 
Acknowledgements          v 
List of Abbreviations         x 
Chapter 1: Regulation of LCPUFA Biosynthesis     1 
1.1 Introduction         1 
1.2 Dietary Sources         1 
1.3 Biosynthesis         3 
1.3.1 Desaturation Reactions      3 
1.3.2 Elongation Reactions      5 
1.4 Efficiency/Rate of Biosynthesis      5 
1.5 Dysregulation of Biosynthesis in Disease     7 
1.6 Regulation by Diet, Hormones, and Drugs     9 
1.7 Areas for Future Research       11 
1.8 Summary of our Approach       12 
1.9 Conclusion         13 
1.10 References         14 
Chapter 2: A Fatty Acid Desaturase Expression Quantitative Trait Locus 
Modulates Response to Simvastatin       23 
 2.1 Abstract          23 
 2.2 Introduction         25 
 2.3 Materials and Methods        27 
  2.3.1 Single SNP association analysis     27 
  2.3.2 Haplotype association analysis     28 
 vii 
  2.3.3 Conserved regions and transcription factor binding   
  predictions         28 
2.3.4 Lymphoblast cell culture, treatments, and RNA extraction 29 
  2.3.5 Quantitative Real-Time PCR     29 
  2.3.6 Sequencing of candidate sterol response element regions 30 
 2.4 Results          31 
  2.4.1 Identification of eQTL associated with FADS1 expression 31 
  2.4.2 Predicted transcription factor binding sites   34 
2.4.3 Lymphoblast FADS1 and FADS2 expression and transcription   
factor agonists        38 
2.4.4 Sequence differences near the putative SREBP-1c binding site in 
FADS2 intron 1        40 
 2.5 Discussion         42 
 2.6 References         48 
Chapter 3: Dietary Long-Chain Polyunsaturated Fatty Acids Upregulate 
Expression of FADS3 Transcripts       51 
 3.1 Abstract          51 
 3.2 Introduction         54 
 3.3 Materials and Methods        56 
  3.3.1 Animals and diets       56 
  3.3.2 Quantitative real-time PCR      56 
  3.3.3 Fatty Acid Analysis       58 
  3.3.4 Cell treatments       59 
  3.3.5 Statistical Methods       59 
 3.4 Results          60 
  3.4.1 FADS expression in baboon liver     60 
 viii 
  3.4.2 Liver PUFA substrate-product ratios    63 
3.4.3 FADS expression in response to LCPUFA supplementation in               
HepG2 cells         65 
 3.5 Discussion          66 
 3.6 References          70 
Chapter 4: The Polypyrimidine Tract Binding Protein Regulates Desaturase 
Alternative Splicing and PUFA Composition      73 
 4.1 Abstract          73 
 4.2 Introduction         74 
 4.3 Materials and Methods        77 
  4.3.1 Cell Culture        77 
  4.3.2 In vitro RNA binding assay      78 
  4.3.3 siRNA         79 
  4.3.4 RNA extraction and PCR      79 
  4.3.5 Fatty Acid Analysis       80 
 4.4 Results          81 
  4.4.1 PTB is predicted to bind FADS2 and FADS3 exonic splice sites  
81 
  4.4.2 PTB is associated with the FADS2 alternative splice site in vitro  
82 
4.4.3 PTB knockdown upregulates FADS2 AT1 and FADS3 AT7 82 
  4.4.4 PTB is inversely correlated with FADS2 AT1 in baboon tissues  
84 
  4.4.5 PTB knockdown specifically decreases omega-3 fatty acid content 
            87 
 4.5 Discussion         91 
 ix 
 4.6 References         96 
Chapter 5: Conclusion and Future Directions     101 
 5.1 References         106 
 
 x 
LIST OF ABBREVIATIONS 
 
ACTH   adrenocorticotropic hormone 
ALA   alpha-linolenic acid, 18:3n-3 
ARA   arachidonic acid, 20:4n-6 
AT   alternative transcript 
BSA   bovine serum albumin 
CS   classically spliced 
DHA   docosahexaenoic acid, 22:6n-3 
DPA   docosapentaenoic acid, 22:5n-3 
ELOVL  elongation of very long chain fatty acids 
eQTL   expression quantitative trait locus 
EPA   eicosapentaenoic acid, 20:5n-3 
ESS   exonic splicing silencer 
FADS   fatty acid desaturase (FADS1, FADS2, FADS3) 
FBS   fetal bovine serum 
HDL   high density lipoprotein 
hnRNP  heteronuclear riboprotein 
InDel   Insertion/Deletion 
IQ   intelligence quotient 
JPT   Japanese in Tokyo International HapMap Project population 
LA   linoleic acid, 18:2n-6 
LCPUFA  long-chain polyunsaturated fatty acid 
LD   linkage disequilibrium 
LDL   low density lipoprotein 
LXR   liver X receptor 
 xi 
mut   mutant 
PPAR   peroxisome proliferator-activated receptor 
PPRE   peroxisome proliferator response element 
PTB   polypyrimidine tract binding protein (also, hnRNP I) 
qRT-PCR  quantitative real-time PCR 
RNAi   RNA interference 
RT-PCR  reverse transcriptase PCR 
RXR   retinoid X receptor 
siRNA   small interfering RNA 
SNP   single nucleotide polymorphism 
SR   serine-arginine 
SRE   sterol response element 
SREBP  sterol response element binding protein 
wt   wild type 
 
 
 
  1 
CHAPTER 1 
REGULATION OF LCPUFA BIOSYNTHESIS 
 
Introduction 
 
The omega-3 and omega-6 long-chain polyunsaturated fatty acids (LCPUFA) play 
important roles in many physiological processes.  Omega-3 and omega-6 LCPUFA are 
precursors for oxygenated lipid mediators known as eicosanoids and docosanoids, 
which convey signals controlling inflammation and blood clotting [1], and affect gene 
expression directly through interaction with nuclear receptors [2].  The LCPUFA 
docosahexaenoic acid (DHA, 22:6n-3) and arachidonic acid (ARA, 20:4n-6) are major 
components of the central nervous system, comprising 25% of structural lipid in gray 
matter [3]. 
 
Dietary sources 
 
DHA and ARA can be obtained pre-formed from dietary sources, or can be synthesized 
starting from alpha-linolenic acid (ALA, 18:3n-3) and linoleic acid (LA, 18:2n-6), 
respectively (Figure 1.1).  ALA and LA are considered essential fatty acids because 
humans cannot synthesize them, so they must be obtained from plant foods.  The most 
recent dietary reference intakes for macronutrients from the Institute of Medicine 
defined Adequate Intakes as 12-17 g/day for LA, and 1.1 – 1.6 g/day for ALA [4].  Flax 
and canola oil are good sources of ALA, and nearly all vegetable and nut oils are 
abundant sources of LA.   DHA and the eicosanoid precursor EPA (eicosapentaenoic  
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Figure 1.1.   Biosynthesis of omega-3 (n-3) and omega-6 (n-6) LCPUFA.    
Nomenclature refers to the number of carbons and double bonds (e.g., 20:5n-3 has 20 
carbons and 5 double bonds, with n-3 describing distance of the double bonds from the 
terminal methyl carbon of the fatty acid.) Fatty acids of special interest include linoleic 
acid (LA, 18:2n-6), alpha-linolenic acid (ALA, 18:3n-3), eicosapentaenoic acid (EPA, 
20:5n-3), arachidonic acid (ARA, 20:4n-6), and docosahexaenoic acid (DHA, 22:6n-3). 
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 acid, 20:5n-3) are mainly found in oily fish such as salmon and mackerel.  No natural 
foods are especially rich in ARA, but it can reach high levels in farmed fish fed corn [5].  
All dietary PUFA, including ALA and LA, have one of three fates, depending on 
physiological needs: incorporation into membrane phospholipids, beta-oxidation to yield 
energy, or biosynthesis of longer-chain polyunsaturated fatty acids. 
 
Biosynthesis 
 
The biosynthetic pathway depicted in Figure 1.1 occurs through alternating steps of 
desaturation (addition of double bonds) and elongation (addition of two carbons) of fatty 
acyl-CoA substrates.  Most of these steps have been reproduced in microsomal 
reactions, so the majority of the pathway is thought to occur in the endoplasmic 
reticulum.  There are sporadic reports of desaturase activity in other membranes, for 
instance, in nuclei [6].    
 
Desaturation Reactions 
 
Desaturase enzymes introduce double bonds into the fatty acid chain, according to the 
general reaction: 
R1-CH2-CH2-R2 + O2 + 2e
- + 2H+  R1-CH=CH-R2 + 2H20 
LCPUFA biosynthesis requires the activity of two desaturases: the delta-6/delta-8 
desaturase, encoded by FADS2, and the delta-5 desaturase, encoded by FADS1.  The 
“delta” terminology refers to placement of the double bond by the number of carbons 
from the carboxyl end of the fatty acid (i.e., delta-5 introduces a double bond 5 carbons 
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from the carboxyl terminus.)  Both enzymes are considered “front-end” desaturases due 
to their ability to introduce a double bond between the omega-9 position and the 
carboxyl (“front”) end of the fatty acid.  A histidine repeat motif common to desaturase 
sequences is thought to coordinate two iron atoms in the active site for some 
desaturase enzymes [7,8], but details of the catalytic mechanism remain to be 
elucidated. Protein has never been purified reproducibly for these integral membrane 
enzymes, and no crystal structures have been reported.  Both enzymes contain an N-
terminal fused cytochrome b5 domain, believed to act as an electron donor for the 
desaturation reaction.  In a plant homolog of the delta-6 desaturase, mutagenesis of the 
heme binding domain of the cytochrome b5 region results in loss of enzymatic activity 
[9].   
The FADS2 enzyme carries out the rate-limiting first step in the biosynthetic pathway, 
converting the essential fatty acids to long-chain PUFA.  In addition, FADS2 has been 
shown to accept 24-carbon fatty acids as substrates, as shown in Figure 1.1.  Delta-8 
desaturation by FADS2 results in the rescue of 20-carbon fatty acids once thought to be 
dead-end products [10].  The FADS1 enzyme is responsible for the step generating the 
important eicosanoid precursors ARA and EPA.  Northern analysis has demonstrated 
that the delta-6 desaturase is most highly expressed in liver, followed by brain, heart, 
and lung; the delta-5 desaturase is most highly expressed in the adrenal gland, followed 
by liver and brain [11]. 
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Elongation Reactions 
The overall reaction for elongation involves the incorporation of two carbons from 
malonyl-CoA into the fatty acyl-CoA substrate at the carboxyl end, with NADPH as the 
reducing agent.  This occurs by four separate enzymatic reactions, with elongases 
catalyzing only the initial, rate-controlling condensation step combining malonyl-CoA 
with the fatty acyl-CoA to generate 3-ketoacyl-CoA.  This product is then reduced to 3-
hydroxyacyl-CoA, followed by dehydration to produce trans-2-enoyl-CoA, then a second 
reduction to the final acyl-CoA product.  The mammalian gene family containing the 
elongases is designated ELOVL, for elongation of very-long-chain fatty acids.  ELOVL2, 
ELOVL4, and ELOVL5 have been shown to prefer PUFA substrates, with ELOVL5 
acting on 18- and 20-carbon PUFA, and ELOVL2 and ELOVL4 acting on >20 carbon 
PUFA [12].  ELOVL5 is expressed ubiquitously, but is highest in liver, testis, and 
adrenal gland [13].  ELOVL2 and ELOVL4 are expressed in only a few tissues, 
particularly liver and testis for ELOVL2 [14,15], and retina, brain, skin and testis for 
ELOVL4 [16]. 
Efficiency/Rate of Biosynthesis 
During the first 10 weeks of pregnancy, blood levels of DHA and ARA increase while LA 
decreases, consistent with enhanced biosynthesis [17].  Beginning in the 17th week of 
gestation, human fetal livers have significant delta-5 and delta-6 desaturase activities in 
microsomal assays [18]. Studies of mouse and bovine mammary gland have 
demonstrated dramatic upregulation of FADS1 and FADS2 at the commencement of 
lactation [19,20], suggesting that nursing mothers have increased biosynthetic 
capability.  However, supplementation of 10 g/day ALA from flaxseed oil in lactating 
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women raised breast milk EPA and DPA (22:5n-3, docosapentaenoic acid), but not 
DHA; the lack of breast milk DHA response was unexpected and seemingly paradoxical 
[21].  DHA levels can be raised by dietary ALA in preterm newborns and young infants, 
at rates indicating far more efficient biosynthesis than in adults [22,23,24], consistent 
with direct measurements showing biosynthesis is far more efficient in fetal [25], 
compared to neonatal [26] primates.  However, a wide range of DHA biosynthetic 
capability has been observed in human infants, with DHA biosynthesis actually 
undetectable in some cases [27]; it is unclear whether these individual differences are 
due to genotype, environmental influences, or some combination of the two.  Adults 
have much lower biosynthetic activity, and numerous studies have shown that less than 
5% of dietary ALA is converted to DHA; consuming pre-formed DHA is the only effective 
way to raise blood levels in adults [28,29,30].  Omega-3 fatty acid biosynthesis is 
especially compromised, in part because about 60% of dietary ALA is oxidized, the 
highest rate known for fatty acids [28].  However, the situation is more complex, since 
supplemental ALA in adults increases blood levels of EPA and DPA, but not DHA; DHA 
derived from biosynthesis can only be increased if dietary LA is decreased at the same 
time as ALA increases [5]. 
Because the biosynthetic enzymes described above act on both omega-3 and omega-6 
fatty acids, final levels of LCPUFA of each class depend on the ratio of omega-6 to 
omega-3 fatty acids consumed in the diet.  ALA and LA compete for the same 
biosynthetic enzymes to be desaturated and elongated into bioactive end-products such 
as ARA, EPA and DHA.  Humans consuming experimental diets with identical total 
PUFA, but differing in LA/ALA ratio, had significantly lower platelet aggregation as the 
omega-6/omega-3 ratio decreased [31].  Within the past 100 years, adoption of new 
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food technology and practices of large-scale agribusiness have resulted in an omega-
6/omega-3 ratio of about 10-15:1 in the modern western diet, compared to an estimated 
ratio of 2:1 or 3:1 throughout the rest of human history [32,33].  In particular, advances 
in production of vegetable oils from seeds have led to dramatic increases in LA 
consumption, at the same time that consumption of wild game and pasture-raised meat 
(with omega-6/omega-3 ratio close to 1) has been replaced by mass-produced farming 
of animals fed grain high in LA [33].  Because the modern Western diet provides 
primarily omega-6 precursors, biosynthesis is more likely to account for ARA levels than 
EPA or DHA.  ARA gives rise to eicosanoids with functions generally opposing those of 
lipid mediators derived from EPA or DHA, so a high omega-6/omega-3 ratio tilts the 
balance toward pro-inflammatory, pro-thrombotic, and pro-arrhythmia effects [2].  In 
addition, the omega-6/omega-3 ratio in phospholipids composing cell membranes alters 
function of the G-protein coupled receptor, rhodopsin [34].  It should be noted, however, 
that effects of differential regulation of biosynthetic pathway enzymes depend very 
much on dietary context; for example, higher desaturase activity might result in higher 
inflammation from ARA-derived eicosanoids in western countries, but not in cultures 
with lower dietary omega-6/omega-3 ratios.   
Dysregulation of Biosynthesis in Disease 
From a public health standpoint, the current emphasis is on the need for increased 
consumption of all omega-3 fatty acids, and especially DHA, but relatively little attention 
has been paid to biosynthesis.  However, genomic studies suggest biosynthesis may be 
more important than previously appreciated.  Single nucleotide polymorphisms (SNPs) 
in enzymes in the biosynthetic pathway have been associated with various physiological 
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conditions, and several diseases are associated with altered expression of desaturases 
and/or elongases.  SNPs in FADS2 have been associated with allergy and atopic 
eczema, total cholesterol, LDL, C-reactive protein levels, and coronary artery disease 
risk, as well as cognitive outcomes such as attention-deficit hyperactivity disorder and 
intelligence quotient (IQ) in children [35,36,37,38,39,40].  SNPs in FADS1 have been 
associated with altered glucose metabolism, LDL, HDL, total cholesterol, triglycerides, 
age-related macular degeneration, coronary artery disease, and IQ 
[36,41,42,43,44,45,46,47,48,49,50].  Minor alleles of SNPs in ELOVL2 are associated 
with reduced DHA and higher EPA and DPA (docosapentaenoic acid, 22:5n-3) levels 
[51].  In addition, several forms of inherited macular degeneration are caused by 
mutations in the ELOVL4 gene [12].  Rats with streptozotocin-induced diabetes have 
reduced expression of both ELOVL2 and ELOVL4 in retina [52], as well as lower 
expression of FADS1 and FADS2 in liver, adrenal gland, and testes [53].  FADS1, 
FADS2, and ELOVL5 were downregulated in skin biopsies from atopic eczema patients 
[54].  Downregulation of FADS1 expression has been observed in the brain frontal 
cortex of suicide completers [55], whereas upregulation of FADS2 was found in the 
prefrontal cortex in autopsy samples from patients with schizophrenia, even in patients 
free of antipsychotic medication [56].  Overexpression of FADS2 was also observed in 
ERBB2-positive breast cancer [57].  Conversely, FADS1 has been reported to be 
silenced by methylation in gastric cancer, but not in normal gastric mucosa [58].  The 
environmental, genetic, or physiological factors that may have produced these changes 
in gene expression have not been elucidated, but identifying regulatory mechanisms 
would improve understanding of these complex disorders. 
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Regulation by Diet, Hormones and Drugs 
Because delta-6 desaturation is known to be rate-limiting, most studies of regulation of 
LCPUFA biosynthesis have focused on modulation of desaturase activity by diet, 
hormones and drugs.   Significant downregulation of FADS1 and FADS2 has been 
observed in adipocytes following weight loss on diets restricted by 600-1100 kcal per 
day, regardless of the percent total fat [59].  The same effect was observed even after a 
3 week isocaloric adjustment period designed to account for changes due solely to 
PUFA composition [60], before commencing the energy restricted diet.   
Dietary PUFA have been shown to suppress SREBP-1 expression [61]. The end-
product DHA is known to down-regulate expression of both FADS1 and FADS2 by 
lowering activity of the sterol response element binding protein 1c (SREBP-1c) [62].  
Other transcription factors that have been implicated in regulation of FADS genes 
include the peroxisome proliferator-activated receptors (PPARs) [63].   FADS1 is 
strongly upregulated in livers of vitamin A-deficient rats, and it is downregulated as 
retinoic acid dose increases [64].  The exact mechanism is unknown, but it is thought 
that retinoic acid may exert its effects by altering RXR binding to LXR, and subsequent 
binding of the heterodimer to the SREBP gene promoter.  ELOVL5 is regulated by 
SREBP-1c in mouse liver [65], and is downregulated by LCPUFA [14].  Both SREBP-1a 
and SREBP-1c have been implicated in regulation of ELOVL2, but the exact 
mechanism is still unclear [12]. 
Many hormones are believed to affect desaturases by genomic mechanisms [53], acting 
on steroid regulatory elements (SREs) [63] or through Peroxisome Proliferator response 
elements (PPREs) [66].  Most hormones decrease desaturase activity, as measured by 
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studies with radiolabeled fatty acids, usually in rodent models.  It should be noted, 
however, that rodents at all ages have much higher constitutive desaturase activity than 
humans, so there may be species-specific differences in desaturase regulation [67].  
Insulin has been demonstrated to increase desaturase activity for both the ∆5- and ∆6-
desaturases in rodent models of diabetes [53]. Glucagon and epinephrine/adrenaline 
decrease desaturase activity by a mechanism involving induction of cAMP [53].  
Adrenocorticotropic hormone (ACTH) also decreases desaturase activity, by both direct 
and indirect modes that are not well understood [68]. Steroid hormones categorized as 
glucocorticoids decrease desaturase activity by directly altering gene expression [69].  
Evidence from controlled feeding studies of humans, including transgender individuals 
(female to male and male to female), have confirmed that females have higher DHA 
status due to estrogenic effects, likely through modulation of desaturases [70]. Higher 
levels of FADS1 and FADS2 mRNA and activity have been observed in livers of female 
rats compared to male rats [71].   
Several pharmacological agents have been shown to affect desaturase activity. 
Although statin drugs primarily are known as inhibitors of HMG-CoA reductase, they 
also have important pleiotropic effects beyond cholesterol reduction, including improved 
endothelial function and reduced inflammation and thrombosis. It has been 
hypothesized that an increase in LCPUFA levels resulting from increased desaturase 
activity is primarily responsible for statins’ pleiotropic effects [72,73].  Intriguingly, high 
omega-3 LCPUFA diets decreased risk for overall and cardiac mortality by the same 
amount as statin treatment [74].  Simvastatin, a statin drug, is known to upregulate 
SREBP-1c levels [75], so the likely mechanism increasing LCPUFA levels is by 
induction of desaturase gene expression via SREBP-1c.  Similarly, antipsychotic drugs 
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of the so-called typical and atypical classes, such as haloperidol and clozapine, 
respectively, upregulate FADS1 and/or FADS2 expression by an SREBP-dependent 
mechanism in human glioma cells [76].  Interestingly, atypical antipsychotic 
medications, approved for schizophrenia treatment but also used off-label for numerous 
mental disorders, are now the top-selling drugs in the United States [77].  In 2005, the 
two best-selling drugs in North America were atorvastatin and simvastatin [78].  Thus, 
the most popular drugs in America are likely to upregulate desaturases as part of their 
effects.  Research is needed to determine whether enhanced LCPUFA biosynthesis 
contributes to the therapeutic benefits of these medications. 
 
Areas for Future Research 
 
Several aspects of the LCPUFA biosynthetic pathway remain to be understood. FADS2 
is alternatively spliced to generate an alternative transcript (FADS2 AT1) with a different 
expression pattern compared to the classical form in primate tissues [79].  The function 
of this alternative splice variant is unknown, but its expression is conserved across 
numerous species [80], suggesting an important physiological role.   
 
FADS1 and FADS2 form part of a 100kb gene cluster on chromosome 11, together with 
a third member of the gene family, designated FADS3.  FADS3 is a putative fatty acid 
desaturase gene due to extensive sequence homology with FADS2 (62%) and FADS1 
(52%), but no function for FADS3 has been found [81].  However, genetic evidence 
suggests FADS3 plays an important role in lipid metabolism and diseases.  For 
example, SNPs in FADS3 are associated with plasma sphingolipids and triglyceride 
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levels, and with risk of myocardial infarction [82,83].  Expression of FADS3 is 
dysregulated in familial combined hyperlipidemia [83], and FADS3 is one of the six most 
highly expressed genes at the embryo implantation site in mouse uterus [84].  
Uncovering a function for FADS3 is made more challenging because FADS3 has seven 
splice variants, each with distinctive patterns of expression in primate tissues [85]. As 
with FADS2 AT1, at least five of these variants were conserved from chickens to 
humans [80], underscoring their importance.  Because of the sequence similarity of 
FADS3 to the other FADS genes, it is reasonable to suppose that its function may 
involve LCPUFA biosynthesis.  However, efforts in our laboratory to find a substrate for 
FADS3 or any of the splice variants have so far been unsuccessful.   
 
Summary of our Approach 
 
The three papers included in this dissertation all are related to the overall topic of 
desaturase regulation.  In the first paper, we adopt a genomics approach to study 
regulation of FADS1 and FADS2.  Since there are no known non-synonymous SNPs in 
coding regions of FADS2, we reasoned that a likely mechanism of action by which 
disease-associated SNPs might function would be by altering FADS gene regulation.  
Accordingly, we investigated genetic variants in the FADS gene cluster for association 
with expression of FADS genes, and differences in response to modulators of SREBP-
1c and PPAR γ.  The second paper examines regulation of FADS3 splice variants in 
response to dietary LCPUFA in infant baboons.  We studied regulation in order to obtain 
clues to FADS3 function.  If the function of FADS3 were similar to those of FADS1 and 
FADS2, then like them, FADS3 should be downregulated by LCPUFA.  We also 
investigated molecular mechanisms by which LCPUFA affected gene expression for the 
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three genes.  Similarly, splicing regulation is examined in the third paper, in which we 
test our hypothesis of a role for a splicing factor in regulating FADS2 and FADS3 
alternative mRNA splicing, and examine fatty acid changes associated with an altered 
splicing pattern.   
Conclusion 
In recent years, increased attention has focused on the importance of LCPUFA 
biosynthesis, after numerous studies have found SNPs and dysregulated expression of 
desaturases associated with diseases.  Diets lacking DHA and EPA are commonplace 
in western cultures, increasing dependence on biosynthesis compared to cultures with 
high seafood consumption.  Genetic and molecular studies are needed to identify 
individuals most at risk for deficiency, and to uncover mechanisms underlying 
desaturase associations with diseases.  Much is still not understood about regulation of 
biosynthesis, and the functions of desaturase alternative splice variants and FADS3 
remain to be found.  Deeper understanding of the remaining mysteries in this field will 
help reveal how genetics and environment interact to bring about individual differences 
in nutritional requirements for the essential omega-3 and omega-6 fatty acids, and may 
lead to strategies for optimizing biosynthesis as an alternative or complement to 
supplementation. 
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CHAPTER 2 
A FATTY ACID DESATURASE EXPRESSION QUANTITATIVE TRAIT LOCUS 
MODULATES RESPONSE TO SIMVASTATIN 
Abstract  
The FADS1 and FADS2 genes encode fatty acid desaturases required for synthesis of 
omega-3 and omega-6 long-chain polyunsaturated fatty acids (LCPUFA) important in 
the central nervous system, inflammatory response, and cardiovascular health.  Single 
nucleotide polymorphisms (SNPs) in these genes are associated with numerous health 
outcomes, but it is unclear how genetic variation affects desaturase enzyme function.  
Here, lymphoblasts obtained from Japanese in Tokyo participants in the International 
HapMap Project were evaluated for association of expression microarray results with 
SNPs in the FADS gene cluster.  Six SNPs in the first intron of the FADS2 gene were 
significantly associated with FADS1 expression after Bonferroni correction.  A 10-SNP 
haplotype in FADS2 (rs2727270 to rs2851682, permuted p = 0.028) present in 24% of 
the population was significantly associated with lower expression of FADS1, confirmed 
by qRT-PCR.  A highly conserved region coinciding with the most significant SNPs 
contained predicted binding sites for PPARγ and SREBP.  Lymphoblasts homozygous 
for either the major or minor haplotype were treated with agonists for these transcription 
factors, and expression of FADS1 and FADS2 measured.  There was no difference by 
genotype in response to the PPARγ agonist rosiglitazone.  The statin drug simvastatin 
and the LXR agonist GW3965 both upregulated expression of FADS1 and FADS2 
through activation of SREBP-1c.  Surprisingly, minor haplotype homozygotes had 20-
40% higher induction of FADS1 and FADS2 after simvastatin or GW3965 treatment, 
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suggesting enhanced responsiveness to SREBP-1c.  Sequencing of the region flanking 
the putative sterol response element (SRE) in FADS2 identified two deletion mutations 
within 150 bp of the putative SRE in all minor haplotype carriers, and none among the 
major haplotype carriers studied.   Individuals carrying the minor haplotype may be 
particularly vulnerable to alterations in diet that reduce LCPUFA intake, such as low fish 
consumption, and may be especially responsive to statin or marine oil therapy.  
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Introduction 
The delta-5 and delta-6 desaturases (encoded by FADS1 and FADS2, respectively) are 
essential for biosynthesis of long-chain omega-3 and omega-6 fatty acids.  These long-
chain polyunsaturated fatty acids (LCPUFA), such as docosahexaenoic acid (DHA) and 
arachidonic acid (ARA), are major components of cell membranes in the central 
nervous system, act as precursors for signaling molecules such as eicosanoids and 
docosanoids, and directly affect gene expression to influence important physiological 
functions such as inflammation and blood clotting [1,2,3].  Although both ARA and DHA 
can be obtained pre-formed through diet, most populations do not consume enough to 
completely remove any dependence on biosynthesis.  Indeed, genetic studies have 
underscored the importance of FADS1 and FADS2 by linking single nucleotide 
polymorphisms (SNPs) in these genes with numerous health outcomes, including 
coronary artery disease, total cholesterol, LDL, C-reactive protein levels, allergy and 
atopic eczema, as well as cognitive outcomes such as attention-deficit hyperactivity 
disorder and IQ in children [4,5,6,7,8,9].   
However, mechanisms describing how gene variants affect FADS gene function are 
lacking, so it is difficult to translate SNP associations into disease prevention or 
treatment.  Despite numerous SNPs in FADS2 associated with health outcomes, there 
are no validated non-synonymous SNPs in the FADS2 gene.  This suggests that 
mechanisms are likely to be regulatory rather than through protein structural changes 
for any causal SNPs in FADS2.  A causal SNP in the promoter region of FADS2 has 
been reported [10], but this SNP is not polymorphic in the Han Chinese, Japanese, and 
Yoruba International HapMap project populations (HapMap Genome browser release 
#28). Thus, this one SNP does not explain all associations found in other world 
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populations.  In addition, this SNP only affects FADS2 expression, so it does not explain 
results in European or majority European-descendent populations suggesting lower ∆5-
desaturase activity associated with some SNPs [11,12,13].   
Some key molecules involved in regulation of FADS1 and FADS2 gene expression 
have been identified, but regulatory regions and functional binding sites within these 
genes have not been fully elucidated.  The FADS genes reside as a cluster on 
chromosome 11 consisting of FADS1, FADS2 and a third putative desaturase 
designated FADS3.  All reported mechanisms for regulation, such as dietary fatty acid 
or hormonal responses, affect both FADS1 and FADS2 in concert.  For example, the 
end-product DHA is known to down-regulate expression of both FADS1 and FADS2 by 
lowering activity of the sterol response element binding protein 1c (SREBP-1c) [14].  
Other transcription factors that have been implicated in regulation of FADS genes 
include the peroxisome proliferator-activated receptors (PPARs) [15].  However, no 
information is available to link specific SNPs and phenotypes with response to specific 
transcription factors. 
Here, we have taken advantage of dense genotyping conducted for the International 
HapMap Project to achieve fine mapping of an expression quantitative trait locus 
(eQTL) in the FADS gene cluster.  Because previous studies have focused mostly on 
European-derived populations, the Japanese in Tokyo (JPT) population was chosen for 
study here.  The JPT population has a different linkage disequilibrium (LD) block 
structure from Europeans, and SNPs have different minor allele frequencies, so that 
results are likely to provide new information complementary to existing studies in 
Europeans.  We evaluated gene expression in lymphoblast cell culture, which controls 
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for environmental and hormonal influences that would otherwise reduce power to detect 
effects; this approach is ideal for a Japanese population, where exposure to pre-formed 
DHA from high seafood consumption in the traditional diet would otherwise confound 
any study of FADS gene expression.  Single SNPs and haplotypes were evaluated for 
association with FADS gene expression, and the region of highest association was 
searched for putative transcription factor binding sites.  Cells were treated with 
transcription factor agonists to test hypotheses, and a novel eQTL associated with 
SREBP-1c response was identified.  Finally, sequencing of the region flanking the 
putative SREBP-1c binding site revealed two nearby deletion mutations specific to 
minor haplotype carriers. 
Materials and Methods 
Single SNP association analysis 
SNP asociations were carried out for SNPs in the FADS gene cluster using publicly 
available data from 46 International HapMap lymphoblast cell lines for the Japanese in 
Tokyo (JPT) population.  Normalized expression data from the Illumina Sentrix Human-
6 Expression BeadChip Microarray were obtained from the Gene Expression Omnibus 
(Series GSE6536) [16,17].  Genotype information for lymphoblast cell lines was 
obtained from the Coriell Institute for Medical Research SNP Browser.  All genotyped 
SNPs were used, excluding those non-polymorphic in the JPT population.  Single SNP 
associations and multiple test correction were carried out in PLINK v1.07 [18] using 
linear regression, with a dominant model chosen because of lack of power in this small 
sample size to detect additive effects.  Individuals or SNPs missing more than 30% of 
genotypes were excluded, as well as SNPs with minor allele frequency below 1%, or p-
  28 
value < 0.001 for deviation from expected frequency of genotypes in the population 
(Hardy-Weinberg equilibrium).   
Haplotype association analysis 
Phase was imputed and haplotypes identified in the Japanese and European (CEU) 
HapMap populations using Haploview v4.2 [19].  Linkage disequilibrium blocks were 
defined by the confidence interval-based algorithm of Gabriel et al. [20].  Identical 
parameters were used to calculate blocks in both populations.  Haplotype associations 
were carried out in PLINK v1.07 by linear regression with an additive model, using the 
max(T) permutation procedure with 10,000 permutations to correct for multiple testing.  
Exclusion criteria were the same as for individual SNP associations, except that SNPs 
or individuals missing more than 10% of genotypes were excluded.  Haplotype allele 
frequencies lower than 5% were also excluded from analysis.    
Conserved regions and transcription factor binding predictions 
Genomic sequence alignment calculating percent identity of multiple species compared 
with the human sequence was carried out with mVISTA 
(http://genome.lbl.gov/vista/mvista/about.shtml) [21].  Predicted transcription factor 
binding sites were identified by TRANSFAC Professional 9.2 database search 
combined with comparative sequence analysis, using rVISTA (regulatory VISTA, 
http://genome.lbl.gov/vista/rvista/about.shtml) [22]. 
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Lymphoblast cell culture, treatments, and RNA extraction 
Immortalized B-lymphocyte (lymphoblast) cell lines from Japanese HapMap participants 
were obtained from the Coriell Institute for Medical Research, and used within 10 
passages of receipt from the repository.  Cells were grown in RPMI 1640 with 2 mM L-
alanyl-glutamine (Sigma) and 15% fetal bovine serum (media and serum obtained from 
HyClone) in a humidified environment at 37°C with 5% CO2.  All experiments were 
conducted on cells grown and treated in parallel in identical media and growth 
conditions.  Cells were treated with 5 μM simvastatin (Sigma), 1 μM GW3965 (Sigma), 
or 20 μM rosiglitazone (Cayman Chemicals), or vehicle for 24 hours before collecting 
lysates. RNA was extracted using the RNeasy kit (Qiagen), and RNA quality was 
checked by agarose gel electrophoresis to verify RNA integrity and by 260/280 nm 
ratios on a NanoDrop 2000 (Thermo Scientific).  cDNA was prepared using the High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems) according to the 
manufacturer’s protocol.   
Quantitative real-time PCR 
Quantitative real-time PCR was carried out using SYBR Green Master Mix (Roche) on a 
LightCycler 480 instrument (Roche).  PCR primers were obtained from Integrated DNA 
Technologies (sequences available upon request), except for 18S, which was obtained 
from Qiagen as a QuantiTect Primer Assay.  PCR reaction efficiency was calculated 
from standard curves, and reactions were assessed by both melting curves and by 
running on agarose gels to verify reaction products and the absence of primer-dimers.  
Quantitative cycle (Cq) values were determined using LightCycler 480 SW1.5.0SP3 
software, version 1.5.0.39 (Roche).  Relative quantification was carried out using the 
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Pfaffl method [23], taking into account reaction efficiency and using multiple reference 
genes for greater accuracy (β-actin, GAPDH, and 18S).   Before proceeding with 
analysis, basal expression was shown to be invariant by vehicle-only treatment for all 
genes studied.  Statistical significance of differences in fold changes between 
genotypes in response to cell treatments (normalized to vehicle treatment for each 
genotype) was assessed by the Mann-Whitney U test.  Bootstrapping and 
randomization techniques were used in REST 2009 software (Qiagen) to calculate 
significance of fold changes normalizing both genotypes to basal expression in major 
allele homozygotes.  
 
Sequencing of candidate sterol response element regions 
A total of about 5 million cells from lymphoblast cultures were harvested for DNA 
extraction. DNA extraction was performed using DNeasy Blood & Tissue Kit (Qiagen).  
A 629 base pair portion (bases 6908015-6908643; GenBank Accession Number 
NT_167190.1) of FADS2 intron 1 and a 291 base pair portion of FADS1 intron 5 (bases 
6882783-6882505; GenBank Accession Number NT_167190.1) flanking the sterol 
regulatory element (SRE) DNA sequence were amplified using the following primer 
pairs: FADS2 forward primer 5’ TTTCTCAAAGGCCGTGGTGT 3’, FADS2 reverse 
primer 5’ AGTGCTAACCACTCCTGGAA 3’ and FADS1 forward primer 5’ ACAGAGAAT 
GAAGGGACGCA 3’, FADS1 reverse primer 5’ ACCCGAAGGAGGCCATATCT 3’. The 
PCR reactions were carried out using GeneAmp High Fidelity PCR System (Invitrogen). 
Thermal cycling conditions were: initial denaturation at 940C for 5 min followed by 35 
cycles of denaturation at 940C for 30 s, annealing at 600C for 45 s and extension at 
720C for 1 min, with a final extension at 720C for 5 min. PCR products were separated 
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on 2% agarose gels, and the DNA bands were gel eluted and purified using PureLink 
Quick Gel Extraction Kit (Invitrogen, USA). The purified products were sequenced at the 
Cornell University Life Sciences Core Laboratories Center. 
 
Results 
Identification of eQTL associated with FADS1 expression 
Lymphoblast cell cultures derived from all 46 Japanese participants in the International 
HapMap Project were used to search for genetic variants associated with FADS gene 
expression.  Archived Illumina expression microarray data was obtained from the Gene 
Expression Omnibus database repository [16,17].  Analysis was carried out on 41 SNPs 
densely covering the FADS gene cluster.  The Manhattan plot shown in Figure 2.1A 
demonstrated a highly significant region located in FADS2 intron 1 that was associated 
with lower FADS1 expression for the minor allele.   Within this region, six SNPs passed 
Bonferroni correction for multiple testing, as shown in Table 2.1.  There were a few 
nominally significant SNPs associated with FADS2 or FADS3 expression, but none of 
these passed correction for multiple testing (not shown).  Analysis of the linkage 
disequilibrium (LD) block structure for the Japanese HapMap population revealed two 
LD blocks in the region of interest, with the most highly significant SNPs primarily in the 
second block.  Three haplotype alleles were observed within Block 2, as shown in 
Figure 2.1B.  SNPs in this block were: rs2727270, rs2727271, rs174576, rs2524299,  
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Figure 2.1.  Expression quantitative trait locus in FADS2 intron 1 and associated 
haplotype blocks in the Japanese HapMap population.  (A) A Manhattan plot of -
log(p-value) vs. distance in Kb is shown for the association of individual SNPs with 
FADS1 expression, with gene annotations above.  Two LD blocks for this population are 
shown, with darkness of shaded cells representing the degree of correlation (R2) 
between pairs of SNPs.  * Marked SNPs were associated with the ratio of arachidonic to 
linoleic acid (a measure of apparent total desaturase activity) in other Asian populations 
[11,24].  (B) Haplotypes for each LD block are shown, with major alleles for each SNP in 
blue, and minor alleles in red.  Recombination between blocks is depicted by the density 
of lines connecting individual haplotypes, and the multiallelic D’ (0.89). 
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Table 2.1.  Single SNPs in FADS2 intron 1 significantly associated with FADS1 
expression.   
 
SNP Base positiona p-value Betab Bonferronic FDRd 
rs2845573 61358484 0.00073 -0.21 0.0299 0.00597 
rs2727270 61359813 0.00073 -0.21 0.0299 0.00597 
rs2727271 61359934 0.00065 -0.21 0.0265 0.00597 
rs2524299 61361358 0.00053 -0.23 0.0216 0.00597 
rs2072114 61361791 0.00073 -0.21 0.0299 0.00597 
rs2851682 61372588 0.00091 -0.21 0.0374 0.00623 
 
a Base positions from NCBI Build 36  
b Linear regression coefficient  
c Bonferroni adjusted p-value 
d False discovery rate (Benjamini-Hochberg method) 
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rs174577, rs2072114, rs174578, rs174579, rs174585, and rs2851682.  The minor 
haplotype present in about one quarter of the population was significantly associated 
with lower FADS1 expression, as summarized in Table 2.2.   
 
To estimate relevance of these results to studies in other populations, the LD block 
structure of the European (CEU) HapMap population is visualized in Figure 2.2.  
Previous large-scale studies, with associated SNPs marked in Figure 2.2, found a 
variety of outcomes associated with the first intron of the FADS2 gene in European-
derived populations.  In particular, fatty acid changes suggestive of lower FADS1 
enzyme activity were found for SNPs in close proximity and in LD with the most highly 
significant region in the Japanese population.   
 
 
Predicted transcription factor binding sites 
To investigate possible causal mechanisms for the lower FADS1 expression associated 
with this minor haplotype, the area immediately surrounding the most strongly 
associated region, and thus most likely to contain the actual causal locus, was 
examined for predicted regulatory elements.  A region highly conserved from zebrafish 
to humans was identified that overlapped the area containing the most highly significant 
associated SNPs, as shown in Figure 2.3.  TRANSFAC database search using the 
bioinformatics tool rVISTA revealed predicted consensus binding sites in the conserved 
region for two transcription factors: peroxisome proliferator-activated receptor gamma 
(PPARγ) and sterol response element binding protein (SREBP).  We hypothesized that 
the significant SNPs identified above could be associated with a genetic variant within 
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Table 2.2.  Haplotype testing for association with FADS1 expression. 
 
Haplotype Frequency Betaa p-value Empirical p-valueb 
CACACATCGA 0.67 0.090 0.061 0.15 
TTATAGACGG 0.24 -0.12 0.010 0.028 
CAAAAAATAA 0.089 0.068 0.36 0.64 
 
a Linear regression coefficient 
b Corrected empirical p-value from max(T) permutation testing, controlling familywise 
error rate 
 
 
  36 
F1 F1, IQ F1 F1, IQ
F1
IQF1
CAD
CAD
 
Figure 2.2.  Haplotype block in European (CEU) HapMap population.  FADS2 intron 
1 is contained within a large single LD block in the European HapMap population. SNPs 
associated with apparent FADS1 activity are in close proximity and in LD with the region 
highly associated with FADS1 expression in the Japanese population.  Abbreviations: 
F1 = SNPs associated with apparent FADS1 activity, inferred from fatty acid 
product/substrate ratios [11,12,13]; IQ = SNPs associated with IQ in breastfed children 
[9,25]; CAD = SNPs associated with coronary artery disease and c-reactive protein 
levels [7]. 
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Figure 2.3.  Conserved region overlapping with significant SNPs in FADS2 intron 
1.  Zoomed-in detail of FADS2 intron 1 in the Manhattan plot of -log(p-value) vs. base 
position depicts association of SNPs in the Japanese HapMap population with FADS1 
expression, with conserved regions depicted below as percent identity with the human 
sequence.  The red box outlines a region overlapping with the area of highest 
significance that is conserved from zebrafish to humans, and contains predicted binding 
sites for SREBP and PPARγ. 
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one of these binding sites, resulting in altered binding of a transcription factor 
responsible for regulating FADS1 expression.   
 
Lymphoblast FADS1 and FADS2 expression and transcription factor agonists 
Follow-up experiments were carried out in Japanese HapMap lymphoblast cell lines 
homozygous for the minor haplotype associated with FADS1 expression, or 
homozygous for the major haplotype.  All available minor haplotype homozygote cell 
lines were used (n = 5), as well as randomly chosen major allele homozygote cell lines 
(n =11).  FADS1 expression was examined by quantitative real-time PCR, confirming 
the initial microarray results showing lower FADS1 expression for minor haplotype 
homozygotes (Figure 2.4A).  
 
To investigate the possibility of a causal genetic variation in a transcription factor 
binding site, cells were treated with drugs acting directly or indirectly on PPARγ or 
SREBP-1c.  The PPARγ agonist rosiglitazone produced identical modest FADS1 
upregulation responses in major and minor allele homozygotes, so the basal difference 
in FADS1 expression was maintained even after rosiglitazone treatment, as shown in 
Figure 2.4.  Next, two drugs of different classes that alter SREBP-1c by distinct 
mechanisms were examined: the statin drug simvastatin, and the LXR agonist GW3965.  
Both treatments upregulated FADS1 by about two-fold in major haplotype homozygotes.  
Unexpectedly, minor haplotype homozygotes responded even more strongly to 
modulators of SREBP-1c; upregulation of FADS1 was 40% higher in response to 
simvastatin, and 25% higher in response to GW3965 for the minor haplotype (Figure  
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Figure 2.4.  Basal FADS1 and FADS2 expression and drug response in 
lymphoblasts homozygous for major or minor haplotypes.  (A) FADS1 expression 
normalized to the major haplotype cells grown under basal conditions (ordinary growth 
media = 1).  Under basal conditions, the minor haplotype homozygotes had significantly 
lower basal FADS1 expression than the major haplotype homozygotes, and this pattern 
persisted with rosiglitazone treatment.  In contrast, simvastatin or GW3965 treatment 
upregulated expression in both genotypes such that they were no longer significantly 
different.  (B) The same data as in (A) expressed as the change in FADS1 expression 
relative to drug treatment, normalized to vehicle treatment (not shown) for each 
genotype.  Minor haplotype homozygotes confirm the findings in (A), showing 
significantly greater fold increase in FADS1 in response to simvastatin and GW3965 
and no difference from major haplotype homozygotes in response to rosiglitazone.  (C) 
FADS2 expression normalized to basal condition for the major haplotype is equivalent 
for the two haplotypes under basal conditions and for rosiglitazone.  Simvastatin and 
GW3965 differentially upregulate haplotype FADS2 expression so that the minor 
haplotype is greater than the major haplotype.  (D) The change in FADS2 expression 
relative to each genotype’s vehicle control is significant for simvastatin and GW3965.  
*p<0.05 
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 2.4B).  These strong responses to SREBP-1c eliminated the difference in FADS1 
expression observed in untreated cells, so that the two genotypes did not significantly 
differ in final FADS1 expression after treatment with simvastatin or GW3965 (Figure 
2.4A). 
 
Although no difference in basal FADS2 expression for each genotype was observed in 
the archived microarray data (not shown), both PPARγ and SREBP-1c have previously 
been implicated as regulators of FADS2 expression.  Thus, FADS2 expression with and 
without the same drug treatments was evaluated.  As shown in Figure 2.4C, the qRT-
PCR results confirmed the microarray results for basal FADS2, with no difference 
between genotypes, and neither genotype showed any response to rosiglitazone 
treatment.  As with FADS1, SREBP-1c modulators produced about a two-fold increase 
in FADS2 levels for major haplotype homozygotes, and minor haplotype homozygotes 
increased FADS2 expression even more in response to simvastatin or GW3965 (Figure 
2.4D).  Because there was no difference in basal FADS2 levels by genotype, final levels 
of FADS2 were at least 20% higher after statin or LXR agonist treatment in minor 
haplotype homozygotes compared to the major haplotype group (Figure 2.4C).  The 
pattern of response for FADS1 and FADS2 is remarkably consistent (Figures 2.4B and 
2.4D) and the differences in the pattern of total expression (Figures 2.4A and 2.4C) are 
due to differences in basal expression. 
Sequence differences near the putative SREBP-1c binding site in FADS2 intron 1 
Based on the difference in response to SREBP-1c, we hypothesized that a sequence 
variation between the major and minor haplotypes might exist within or in close 
proximity to a putative sterol response element (SRE) binding site for SREBP-1c.  
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Analysis of FADS1 and FADS2 genes with the rVISTA program revealed two decamer 
SREs, one in FADS2 intron 1 (5’-ATCACCCCAC-3’), and another in FADS1 intron 5 (5’-
ATCACGCCAC-3’).  The sequencing of a 291 base pair (bp) fragment flanking the SRE 
DNA sequence of FADS1 showed no differences between the major and minor 
haplotypes. However, sequencing of a 629 bp fragment flanking the SRE DNA 
sequence of FADS2 showed two insertion/deletion (InDel) variants exclusively in the 
minor haplotype.  As shown in Table 2.3, a 22 bp deletion (rs66698963) was identified 
by sequencing in all five minor haplotype homozygotes within a variable number tandem 
repeat minisatellite sequence located 137 bases downstream of the putative SRE.  In 
addition, a 3 bp deletion (-CCA, rs138766446) located 81 bases downstream of the 
putative SRE was observed in all but one of the minor haplotype homozygotes, with the 
remaining one individual missing only one of the 3 bp (-A, rs149597144).  Interestingly, 
the individual with the -A deletion instead of -CCA consistently had the highest basal 
FADS1 expression of all of the minor haplotype homozygotes (data not shown).  None 
of these deletions were observed in any of the eleven major haplotype homozygotes.   
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Table 2.3.  InDel Mutations near the putative SRE in FADS2 intron 1.   
 
ID number 
 
Sequence Distance to 
SRE (bp) 
Minor 
haplotype 
rs66698963 - / 
ACTTCTCCCTGCCTCCCCAGGG 
137 Deletion 
rs138766446 
or 
rs149597144 
 
- / CCA or - / A 
 
81 or 83 
 
Deletion 
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Discussion 
Here, single SNPs and a haplotype in FADS2 intron 1 were found to be significantly 
associated with FADS1 expression, measured by both microarray and independently by 
qRT-PCR.  The FADS2 gene is positioned immediately adjacent at a distance of          
11.3 kb to FADS1 in a head-to-head orientation [26], so that FADS2 intron 1 is 
upstream of the transcription start site for FADS1.  Thus, the existence of an important 
regulatory region for FADS1 transcription in intron 1 of the FADS2 gene is quite 
plausible.  It has been shown that CYP1A1 and CYP1A2 genes that are adjacent to 
each other in head-to-head orientation on human chromosome 15 share common 
bidirectional regulatory regions [27]. The region most highly associated with FADS1 
expression overlapped with a conserved region containing predicted binding sites for 
PPARγ and SREBP.  In follow-up experiments, no difference was observed in response 
to a PPARγ agonist, rosiglitazone, but homozygotes for a minor haplotype were 
significantly more sensitive to expression regulation by SREBP-1c modulation.  The 
enhanced response to SREBP-1c was consistently observed for drugs activating 
SREBP-1c by two different mechanisms: the statin simvastatin upregulates SREBP-1c 
levels as part of its pleiotropic effects [28], and the LXR agonist GW3965 stimulates the 
LXR/RXR heterodimer to activate SREBP-1c [29].  Both genotypes upregulated both 
FADS1 and FADS2 in response to the drugs, but homozygotes for the minor haplotype 
exhibited a significantly greater increase in expression of both genes after drug 
treatment.  Minor haplotype homozygotes had final FADS1 levels equivalent to major 
haplotype homozygotes, and 20% higher FADS2 levels.  The minor haplotype was thus 
associated with two paradoxical states: lower FADS1 expression in the basal state, and 
stronger upregulation of FADS1 and FADS2 in response to SREBP-1c.  The results 
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suggest that the minor haplotype is associated with enhanced response to SREBP-1c in 
a binding site with shared regulatory activity for both FADS1 and FADS2.  These 
findings do not explain the reason for lower FADS1 expression in the basal state, but it 
is possible that a mutation that enhances SREBP-1c binding may be mutually exclusive 
to binding of another transcription factor in a shared binding region. Sequencing of the 
candidate region in FADS2 led to the identification of two deletion mutations present 
only in the minor haplotype homozygotes, located 81 and 137 bases downstream of the 
putative SREBP-1c binding site.  Although the close proximity to the SRE is highly 
suggestive of a causal role, further in vitro experimentation is needed to determine 
whether these InDel mutations affect SREBP-1c binding and activity. 
LCPUFA biosynthesis via FADS-encoded desaturase activity is redundant with direct 
dietary intake of preformed LCPUFA, specifically 20:4n-6, 20:5n-3 and 22:6n-3.  Fish 
intake is recommended in part for its high content of LCPUFA.  The traditional Japanese 
diet delivers on average more than one gram of LCPUFA daily through regular fish 
consumption [30].  At these levels, only minimal biosynthesis of LCPUFA from linoleic 
and linolenic acids is metabolically necessary at any life stage, and any differences in 
desaturase expression and consequent LCPUFA biosynthetic activity between major 
and minor haplotypes would be masked and presumably of little health consequence.  
In contrast, typical North American diets provide, on average, less than 300 mg 
LCPUFA cholesterol total, and thus biosynthesis may be much more important.  
Our in vitro results on human lymphoblasts appear to be relevant to free living humans.  
Previous studies in Asian populations have linked SNPs in this region with serum fatty 
acid changes consistent with lower total desaturase activity (noted in Figure 2.1), 
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suggesting that the genetic associations observed here can be replicated in human 
populations.  These previous studies suggest that the usual state for individuals carrying 
these genetic variants is to have basal FADS1 levels so low that they become rate-
limiting, reducing overall synthesis of fatty acid end-products.  If this is the case, 
individuals with the minor haplotype may particularly benefit from diets incorporating 
higher levels of preformed LCPUFA from fatty fish or marine oil supplements to 
augment biosynthesis.  Thus, although the minor haplotype is common (present in 
about one quarter of the Japanese HapMap population), any detrimental effects of the 
minor genotype are likely to be masked by the large amounts of fatty fish in the 
traditional Japanese diet.  Importantly, the prevalence of this genetic variant may 
represent an additional risk to adopting a western diet for many individuals of Japanese 
descent.  Put another way, individuals with the minor haplotype are predicted to be 
particularly vulnerable to ill-health when adopting diets that severely reduce preformed 
LCPUFA intake.   
Further studies are needed to determine whether the expression results extend to other 
populations.  Our data suggest the hypothesis that in populations with low LCPUFA 
intake, possibly due to low fish consumption, individuals with these genetic variants may 
have a conditional requirement for LCPUFA.  At least some of these populations, such 
as Americans, derive cardiovascular benefits from statins.  A number of previous 
studies have associated SNPs in FADS2 intron 1 with apparent FADS1 enzyme activity 
in large studies of European-derived populations (Figure 2.2), suggesting that the same 
causal locus may exist in Europeans as well as Japanese.  Figure 2.2 also shows that 
the same region has been associated with IQ in breastfed children, but several studies 
in various European populations have produced conflicting and sometimes paradoxical 
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results that were not accounted for by differences in fish consumption between 
populations [6,9].  However, these studies did not take into account cholesterol, an 
activator of SREBP-1c [29] present in breastmilk but not in infant formula; population 
differences in maternal dietary fatty acids and phytosterols may affect breastmilk and 
infant plasma cholesterol and phytosterol levels [31,32,33].  In addition, individuals with 
the minor haplotype might have lower FADS1 expression in the absence of SREBP-1c 
activators (such as with infant formula, which does not contain cholesterol), but higher 
total FADS gene expression in the presence of cholesterol (breastmilk); a similar trend 
of significantly lower IQ in formula-fed, and almost-significant higher IQ in breastfed 
children, was observed in one IQ study for several SNPs in FADS2 intron 1 [9].    
SNPs nearby and in LD with the SNPs most strongly associated with FADS1 expression 
here have also been associated with coronary artery disease in European studies 
(Figure 2.2).  Thus, the finding of enhanced responsiveness to simvastatin for the minor 
haplotype may be of special interest.  Statins have long been known to increase 
LCPUFA levels, and there is some previous evidence of changes in apparent 
desaturase activity in response to statin treatment [34,35].  Although statins primarily 
are known for lowering cholesterol by inhibiting HMG-CoA reductase, they also have 
numerous pleiotropic effects that contribute to their medical benefits, including improved 
endothelial function and reduced inflammation and thrombosis. It has been theorized 
that statins’ pleiotropic effects may be primarily due to alterations in LCPUFA levels 
[35].  Interestingly, diets high in omega-3 LCPUFA were found to reduce overall and 
cardiac mortality by the same amount as statin treatment [36].  Here, we show that 
simvastatin upregulates both FADS1 and FADS2.  The minor haplotype identified here 
was associated with an especially strong response to simvastatin.  Assuming living 
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humans have similar responses as observed in lymphoblasts, individuals with the minor 
haplotype may have lower basal FADS1 expression, leading to lower LCPUFA 
production.  Fortunately, simvastatin is shown here to correct the basal deficiency in 
FADS1 expression, and to produce FADS2 expression that would be higher than in 
other statin users; our results predict that minor haplotype carriers would have 
especially high LCPUFA synthesis after simvastatin treatment, and thus would 
especially benefit from pleiotropic effects attributed to LCPUFA production. 
Our results highlight an extreme example of gene-environment interaction, in which        
a minor haplotype is associated with either lower, or higher, desaturase expression 
depending on levels of SREBP-1c or LXR agonists.  Environmental factors can be 
adjusted to mitigate potential harm for minor haplotype carriers: diet can easily be 
modified to enhance SREBP-1c or LXR activity via natural ligands, or to take in pre-
formed LCPUFA and minimize the need for biosynthesis.  Moreover, carriers of this 
minor haplotype who are candidates for statin treatment may especially benefit from 
these drugs, as well as possibly from future LXR agonist drugs currently under 
development.   
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CHAPTER 3 
DIETARY LONG-CHAIN POLYUNSATURATED FATTY ACIDS UPREGULATE 
EXPRESSION OF FADS3 TRANSCRIPTS 
 
 
Abstract  
The fatty acid desaturase gene family at 11q12-13 includes FADS1 and FADS2, both 
known to mediate biosynthesis of omega-3 and omega-6 long-chain polyunsaturated 
fatty acids (LCPUFA).  FADS3 is a putative desaturase due to its sequence similarity 
with FADS1 and FADS2, but its function is unknown.  We have previously described 7 
FADS3 alternative transcripts (AT) and 1 FADS2 AT conserved across multiple species.  
This study examined the effect of dietary LCPUFA levels on liver FADS gene 
expression in vivo and in vitro, evaluated by qRT-PCR.  Fourteen baboon neonates 
were randomized to three diet groups for their first 12 weeks of life: C: Control, no 
LCPUFA; L: 0.33% docosahexaenoic acid (DHA)/ 0.67% arachidonic acid (ARA) (w/w); 
and L3: 1.00% DHA/ 0.67% ARA (w/w).  Liver FADS1 and both FADS2 transcripts were 
downregulated by at least 50% in the L3 group compared to controls.  In contrast, 
FADS3 AT were upregulated (L3>C), with four transcripts significantly upregulated by 
40% or more.  However, there was no evidence for increased liver fatty acid 
desaturation to coincide with increased FADS3 expression.  Significant upregulation of 
FADS3 AT was also observed in human liver-derived HepG2 cells after DHA or ARA 
treatment.  The PPARγ antagonist GW9662 prevented FADS3 upregulation, while 
downregulation of FADS1 and FADS2 was unaffected.  Thus, FADS3 AT were directly 
upregulated by LCPUFA by a PPARγ-dependent mechanism unrelated to regulation of 
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other desaturases.  This opposing pattern and mechanism of regulation suggests a 
dissimilar function for FADS3 AT compared to other FADS gene products. 
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Introduction 
Biosynthesis of long-chain polyunsaturated fatty acids (LCPUFA) requires introduction 
of cis double bonds by the ∆5 and ∆6 desaturases, encoded by the FADS1 and FADS2 
genes, respectively.  FADS1 and FADS2 span a 100kb cluster on the long arm of 
chromosome 11 (11q12-13.1), together with a third member of the gene family, 
designated FADS3.  FADS3 is a putative fatty acid desaturase gene due to its high 
degree of sequence homology with FADS2 (62%) and FADS1 (52%), but no function for 
FADS3 has been demonstrated experimentally [1].   
 
Although its exact function is unknown, genetic evidence suggests FADS3 plays an 
important role in lipid metabolism and diseases.  For example, single nucleotide 
polymorphisms in FADS3 have been associated with plasma sphingolipids and 
triglyceride levels, and with risk of myocardial infarction [2,3].  Expression of FADS3 is 
altered in familial combined hyperlipidemia [3], and FADS3 is one of the six most highly 
expressed genes at the implantation site in mice at the initiation of pregnancy [4].   
 
Early attempts in our laboratory to characterize FADS3 expression resulted in the 
discovery of seven alternative transcripts (AT) of FADS3 with distinctive patterns of 
expression in primate tissues [5].  In addition, we recently reported an alternative splice 
variant for FADS2 [6].  FADS2 AT1 and at least five of the FADS3 AT were conserved 
from chickens to humans [7].  Despite this evidence of crucial roles in essential 
processes, functions of the splice variants remain unclear. 
Patterns of regulation can often provide clues to function; we reasoned that if the 
FADS3 AT encoded functional fatty acid desaturases, they were likely to be regulated 
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similarly to the classical desaturase genes, FADS1 and FADS2.  These two genes 
encode desaturases required for biosynthesis of the omega-3 and omega-6 LCPUFA 
docosahexaenoic acid (DHA, 22:6n-3) and arachidonic acid (ARA, 20:4n-6).  These two 
products of the biosynthetic pathway have been shown to decrease the classical 
transcripts of FADS1 and FADS2 [8].  DHA and ARA are both known to bind members 
of the peroxisome proliferator-activated receptor (PPAR) family of transcription factors 
(especially PPARα and PPARγ), which form heterodimers with the retinoid X receptor 
(RXR) and influence gene expression [9,10].  The effect of dietary LCPUFA on FADS1 
and FADS2 gene expression has been shown to occur via PPARα and the sterol 
response element binding protein, SREBP-1c [11].  Nutrients, hormones, and drugs 
regulating FADS1 and FADS2 are known to regulate both in concert, with the same 
directionality of change [12], as would be expected for genes functioning in the same 
biosynthetic pathway.   
 
Here we asked whether dietary LCPUFA affect expression of FADS3 AT and FADS2 
AT1 similarly to classical FADS1 and FADS2, both in vivo and in vitro.  Neonatal 
baboons were fed infant formula with varying levels of DHA and ARA for 12 weeks, and 
liver fatty acids and FADS gene expression examined.  In vitro, human liver-derived 
HepG2 cells were studied to determine whether the observed effects were reproducible 
in human cells, and if it was a direct response to a fatty acid or an endocrine response. 
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Materials and Methods 
 
Animals and diets 
All baboon work was carried out at the Southwest Foundation for Biomedical Research 
(SFBR) in San Antonio, TX.  Animal protocols were approved by the SFBR and Cornell 
University Institutional Animal Care and Use Committee (IACUC, protocol # 02-105.)  
Diets and feeding protocols were described in detail previously [13].  Briefly, fourteen 
baboon neonates were randomized to one of three diet groups with varying 
concentrations of ARA and DHA, as described in Table 3.1.  The infant formulas used 
for C and L groups correspond to the human infant formulas Enfamil and Enfamil LIPIL, 
respectively, and the L3 group was targeted to have three-fold higher DHA 
concentration, corresponding with the upper end of DHA levels found in human breast 
milk worldwide [14].  These diets were identical to a subset of those used in recently 
reported human studies [15,16].  As shown in Table 3.1, analysis of the prepared diets 
showed that the actual concentrations used were slightly higher than target values, 
since the diets were prepared within tolerances designed to account for losses and 
variation during manufacturing and storage. Infant baboons consumed the experimental 
diets until 12 weeks of life, when tissues were harvested for lipid and RNA extraction.   
 
Quantitative real-time PCR 
Baboon liver RNA was extracted as described previously [5]. For HepG2 cells, RNA 
was extracted using the RNeasy kit (Qiagen), and RNA quality was checked by agarose 
gel electrophoresis to verify RNA integrity and by 260/280 nm ratios on a NanoDrop  
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Table 3.1.  Characteristics of experimental groups and diets 
 C L L3 
Number of animals (n) 5 4 5 
Female 4 3 3 
Male 1 1 2 
DHA (% w/w) 0 0.42 ± 0.02 [0.33] 1.13 ± 0.04 [1.00] 
ARA (% w/w) 0 0.77 ± 0.02 [0.67] 0.71 ± 0.01 [0.67] 
Analyzed concentrations are shown as mean ± SD; target values are shown in brackets. 
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2000 (Thermo Scientific).  cDNA was prepared using the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems) according to the manufacturer’s protocol.  
Quantitative real-time PCR was carried out using SYBR Green Master Mix (Roche) on a 
LightCycler 480 instrument (Roche).  Human and baboon PCR primers were obtained 
from Integrated DNA Technologies (sequences available upon request), except for 18S, 
which was obtained from Qiagen as a QuantiTect Primer Assay. PCR primers designed 
for FADS splice variants were validated by cloning and sequencing PCR products. PCR 
reaction efficiency was calculated from standard curves, and reactions were assessed 
by both melting curves and by running on agarose gels to verify reaction products and 
the absence of primer-dimers.  Quantitative cycle (Cq) values were determined using 
LightCycler 480 SW1.5.0SP3 software, version 1.5.0.39 (Roche).  Relative 
quantification was carried out using the method of Pfaffl [17], taking into account 
reaction efficiency and using multiple reference genes for greater accuracy (β-actin and 
GAPDH for baboon experiments; β-actin, GAPDH, and 18S for HepG2 cell 
experiments).    
 
Fatty acid analysis 
Lipids from baboon liver samples were extracted and fatty acids analyzed by covalent 
adduct chemical ionization tandem mass spectrometry as described in detail previously 
[13].  Percent conversion of substrates (S) to products (P) was calculated as: [(P) / (S + 
P)] * 100, and normalized to the control group.   
 
Cell treatments 
For all experiments, human HepG2 hepatocellular carcinoma cells were maintained 
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within ten passages of the original passage received from the ATCC.  HepG2 cells were 
grown in MEM with 10% FBS (media and serum obtained from HyClone) in a humidified 
environment at 37°C with 5% CO2.  For fatty acid treatment, free fatty acids were first 
non-covalently bound to fatty-acid free bovine serum albumin (BSA).  Fatty acid sodium 
salts were suspended in PBS, then mixed with fatty-acid free bovine serum albumin 
(U.S. Biologicals) in a 3:1 ratio of fatty acid to albumin, and incubated for 5 hours at 
37°C.  Fatty acids conjugated to albumin were sterilized by passage through a syringe 
filter before cell treatments.  Cells were treated with 100 µM of DHA-BSA, ARA-BSA, 
palmitic-BSA, and/or 2 µM GW9662 (Sigma) for 78 hours in media containing 0.5% 
FBS.   
 
Statistical methods 
Data are presented as mean ± standard deviation.  Bootstrapping and randomization 
techniques were used in REST 2009 software (Qiagen) to calculate significance of fold 
changes in expression for qRT-PCR experiments.  Statistical analysis of changes in 
fatty acid conversion was conducted using Student’s t-test to compare LCPUFA 
supplementation with control.  Linear regression analysis of fatty acid data was carried 
out in SAS v.9.2. 
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Results 
 
FADS expression in baboon liver  
The splicing and expression patterns of the seven alternative transcripts (AT) of FADS3 
and the one splice variant for FADS2 have been described in detail previously [5,6].  
Because of shared sequences across transcripts, it was not possible to design PCR 
primers unique to the full-length FADS3 classical transcript.  However, the splice 
variants could each be assessed by quantitative real-time PCR (qRT-PCR), with the 
exception of FADS3 AT2, which was present at levels too low to quantify accurately.  
Thus, to assess the effect of dietary LCPUFA on FADS3 expression, six of the 
alternative transcripts were evaluated by qRT-PCR in samples obtained from baboon 
livers after 12 weeks on diets L3, L, or C (described in Materials and Methods).  As 
shown in Figure 3.1, FADS3 AT1, AT3, AT4, and AT7 were about 40% upregulated in 
the highest LCPUFA group, L3, relative to control.  FADS3 AT5 and AT6 also had 
apparently elevated mean expression in L3, but it was not statistically significant.  
However, FADS3 AT5 was significantly upregulated in the intermediate group L 
compared to control.  Interestingly, AT1 and AT7 had a significant U-shaped expression 
response, with lower expression in L compared to control, but higher expression in L3.  
 
As shown in Figure 3.2, the other two members of the FADS gene cluster had an 
entirely different pattern of regulation.  FADS1, FADS2, and the alternative transcript 
FADS2 AT1 were all downregulated in both the L and the L3 groups relative to control.  
The magnitude of expression change was similar for both genes; FADS1 and total 
FADS2 transcripts were reduced by at least 50% for both L and L3.    These data are  
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Figure 3.1.  FADS3 isoform expression is altered by dietary LCPUFA.  FADS3 
splice variant expression in livers from baboons fed diet C (gray bars), L (striped bars), 
or L3 (black bars) was measured by qRT-PCR, with GAPDH and beta-actin as 
reference genes.   Most isoforms were significantly upregulated in the L3 diet relative to 
C (* p < 0.05 compared to C).  Downregulated AT1 and AT7, and upregulated AT5, 
were observed for the intermediate diet, L. 
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Figure 3.2.  FADS1 and both FADS2 isoforms are downregulated by dietary 
LCPUFA.  Expression in baboon liver from animals fed diet C (gray bars), L (striped 
bars), or L3 (black bars) was measured by qRT-PCR, with GAPDH and beta-actin as 
reference genes.  * p < 0.05 compared to C group. 
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consistent with previous studies showing lower appearance of labeled 22:6n-3 from 
labeled 18:3n-3 in liver and blood pools 22:6n-3 in a diet with DHA-ARA similar to the 
present L diet  compared to the C diet [18]. 
 
Liver PUFA substrate-product ratios 
To investigate whether FADS3 upregulation affected desaturase reactions, levels of 
fatty acid substrates and products in baboon liver were evaluated as indicators of 
apparent desaturase activity.  DHA and ARA were not included in ratios because their 
concentrations reflected both biosynthesis and incorporation pre-formed from the 
experimental diets.  Instead, several other substrate/product pairings were used to infer 
activity, as shown in Figure 3.3.   FADS2-encoded ∆6-desaturase activity catalyzes the 
desaturation of 18:2n-6 to 18:3n-6.  The percent conversion to the 18:3n-6 product was 
significantly decreased in L compared to C, but L3 was not significantly different from 
control, though the L and L3 means were similar.  Diet 20:4n-6 is zero in the C 
treatment and 0.64 % (w/w) in both the L and L3 treatments, consistent with the concept 
that ARA downregulated both L and L3.   
 
Conversion of 22:4n-6 to 22:5n-6 is presumed to proceed via FADS2-mediated ∆6-
desaturation.  A linear regression against diet DHA yielded a significant slope (p<0.05) 
and thus a significant downward trend for decreasing percent conversion with 
increasing LCPUFA.  The pairing of 18:3n-3 with the downstream product 20:5n-3 was 
used as an aggregate measure of total desaturase activity, since both FADS1 and 
FADS2 gene products are required for 20:5n-3 synthesis.  Substrate conversion  
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Figure 3.3.  Apparent desaturase activity is consistent with downregulation.  
Percent conversion of fatty acid substrates into desaturated products (ratios shown, 
calculated as product/[substrate + product]) was measured in baboon liver and 
normalized to C group (gray bars).  Group L is shown as striped bars, and L3 as black 
bars.  * p < 0.05 compared to C group.  
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resulting in 20:5n-3 was significantly decreased in L3 compared to C.  Finally, a reaction 
catalyzed by a desaturase outside the FADS cluster, the conversion of 18:0 to 18:1 by 
stearoyl-coA desaturase, was also examined since this conversion is sensitive to overall 
dietary unsaturation.  The downward trend in mean conversion with increasing LCPUFA 
was not significant.  Thus, significant differences in pairwise comparisons and trends 
associated with more unsaturation implied steadily decreasing desaturation activity with 
increasing dietary LCPUFA.  No substrate-product pairs were significantly increased by 
dietary LCPUFA, leaving no obvious candidates for FADS3 substrates.   
 
FADS expression in response to LCPUFA supplementation in HepG2 cells  
To investigate the mechanism for the effect of LCPUFA on FADS3 transcripts, human 
liver-derived HepG2 cells were grown in low-serum media supplemented with albumin-
bound fatty acids.  Cells were treated either with docosahexaenoic acid (DHA, 22:6n-3) 
alone, arachidonic acid (ARA, 20:4n-6) alone, or palmitic acid (16:0) as a control.  As 
summarized in Table 3.2, DHA alone significantly upregulated all FADS3 transcripts 
except AT7.  ARA alone significantly upregulated FADS3 AT1 and AT3, while FADS3 
AT4, AT6, and AT7 increases were comparable to those observed with DHA treatment, 
but were not statistically significant.  As in baboon livers, both fatty acids also 
significantly downregulated FADS1 and both FADS2 transcripts.   
 
To understand the role of transcription factors in mediating these expression changes, 
the effect of co-incubation of fatty acids with the PPARγ antagonist GW9662 was 
evaluated.  GW9662 treatment completely blocked the upregulation of FADS3  
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Table 3.2.  Fold changes in FADS gene expression in HepG2 cells for LCPUFA 
treatments with or without the PPARγ antagonist GW9662, shown relative to 
control (palmitic acid). 
Gene DHA 
DHA + 
GW9662 ARA 
ARA + 
GW9662 
FADS3 AT1 1.2** 1.1 1.3** 1.1 
FADS3 AT3 1.2** 1.0 1.2** 1.1 
FADS3 AT4 1.2* 0.93 1.2 1.1 
FADS3 AT5 1.4* 0.92 0.91 1.1 
FADS3 AT6 1.6** 0.85 1.4 0.92 
FADS3 AT7 1.2 0.90 1.2 0.93 
FADS2 0.59** 0.37** 0.47** 0.22** 
FADS2 AT1 0.47** 0.34** 0.32** 0.31** 
FADS1 0.81** 0.50** 0.65** 0.49** 
* p < 0.05, ** p < 0.01 for being different from 1 (control = palmitic acid) 
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transcripts observed with both DHA and ARA treatment, but had no effect on the 
downregulation of FADS1 or FADS2 transcripts.   
 
Discussion 
We have evaluated transcriptional changes in FADS genes in infant baboon liver in 
response to diets corresponding to the physiological range of LCPUFA found in human 
breastmilk worldwide.  FADS3 transcripts followed a pattern of regulation opposite to 
the other members of the FADS gene cluster, FADS1 and FADS2.  FADS3 transcripts 
were upregulated by approximately 40% in livers of animals fed the highest LCPUFA 
diet, L3, compared to control.  In contrast, the same diet downregulated FADS1, 
FADS2, and the alternative transcript FADS2 AT1, by at least 50%.  The similarity of the 
downregulation of FADS2 and FADS2 AT1 suggests transcription-level control rather 
than any change in splicing regulation.   
 
The expression changes observed in baboon liver were reproduced in human liver-
derived HepG2 cells treated with either DHA or ARA.  DHA produced statistically 
significant fold changes in FADS3 isoforms, while ARA treatment produced similar 
magnitude fold-changes, though most were not statistically significant.  Thus, there was 
no obvious difference in sensitivity of the FADS3 response to DHA or ARA, but the DHA 
response had greater precision in this experiment.  Moreover, because the cell 
treatments did not differ in caloric or fat content from the control (palmitic acid 
treatment), the response was a specific, direct response to DHA or ARA rather than an 
endocrine mechanism or a general response to energy density of the diet/media.  Both 
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DHA and ARA have previously been shown to bind and activate the transcription factor 
PPARγ [19].  Co-incubation with the PPARγ antagonist GW9662 prevented FADS3 
upregulation by DHA or ARA, suggesting that the fatty acids acted by a PPARγ-
dependent mechanism.  In contrast, GW9662 did not prevent the downregulation of 
FADS1 and both FADS2 isoforms by DHA or ARA.  Thus, FADS3 expression is 
regulated in opposite sense to the other FADS genes, and occurs by a different 
mechanism. 
 
Extensive substrate screening in our laboratory has so far failed to uncover a substrate 
for any FADS3 isoforms (unpublished data).  Investigation of baboon liver fatty acids as 
evidence of desaturase enzyme activity produced evidence for downregulation of 
FADS1 and FADS2, but no evidence for increased desaturation of any 
substrate/product pair to correspond with the upregulation of FADS3 isoforms.  This 
observation could be explained if FADS3 isoforms function as desaturases on non-
LCPUFA substrates.  Alternatively, they may act as non-functional dominant negative 
inhibitors by binding non-productively to LCPUFA substrates, and removing them from 
availability for desaturase reactions.  In favor of the latter theory, ∆5-desaturase, ∆6-
desaturase, and stearoyl-coA desaturases are all downregulated by dietary unsaturated 
fatty acids [20,21], probably as a mechanism to maintain the unsaturation index of cell 
membranes within certain limits.  It is difficult to reconcile the opposite pattern of 
regulation of FADS3 with a putative function as a desaturase.  Moreover, dominant 
negative inhibition is a common mode of action for splice variants of other enzymes 
[22], and binding specificity for different fatty acids could explain the large number of 
splice variants for FADS3.  Further studies are required to test this hypothesis. 
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We have demonstrated that FADS3 is regulated by a different mechanism from other 
members of the FADS gene cluster, and expression is upregulated when other 
desaturases are downregulated.  These results suggest that, despite a high degree of 
sequence similarity, FADS3 isoforms have a function quite distinct from FADS1 and 
FADS2, and may not encode functional desaturases at all.  FADS3 has been implicated 
in cardiovascular conditions of enormous public health import, so determining the true 
function of FADS3 and its alternative transcripts should be a high priority.  Further work 
characterizing regulation of FADS3 transcription and alternative mRNA splicing may 
yield more clues to functional roles. 
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CHAPTER 4 
THE POLYPYRIMIDINE TRACT BINDING PROTEIN REGULATES DESATURASE 
ALTERNATIVE SPLICING AND PUFA COMPOSITION 
 
Abstract 
 
The delta-6 desaturase, encoded by FADS2, plays a crucial role in omega-3 and 
omega-6 fatty acid synthesis. These fatty acids are essential components of the central 
nervous system, and act as precursors for eicosanoid signaling molecules and as direct 
modulators of gene expression.  The polypyrimidine tract binding protein (PTB, or 
hnRNP I), is a splicing factor that regulates alternative pre-mRNA splicing.  Here, PTB is 
shown to bind an exonic splicing silencer element and repress alternative splicing of 
FADS2 into FADS2 AT1.  PTB and FADS2AT1 were inversely correlated in neonatal 
baboon tissues, implicating PTB as a major regulator of tissue-specific FADS2 splicing.  
In HepG2 cells, PTB knockdown modulated alternative splicing of FADS2, as well as 
FADS3, a putative desaturase of unknown function.  Omega-3 fatty acids decreased by 
nearly one half relative to omega-6 fatty acids in PTB knockdown cells compared to 
controls, with a particularly strong decrease in eicosapentaenoic acid concentration and 
its ratio with arachidonic acid.  This is a rare demonstration of a mechanism specifically 
altering the cellular omega-3 to omega-6 fatty acid ratio without any change in 
diet/media.  These findings reveal a novel role for PTB, regulating availability of 
membrane components and eicosanoid precursors for cell signaling.    
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Introduction 
 
The delta-6/delta-8 desaturase, encoded by FADS2, is the rate-limiting enzyme in 
synthesis of long-chain (20-carbon and above) omega-3 and omega-6 polyunsaturated 
fatty acids (PUFA) (Figure 4.1).  These fatty acids constitute about 25% of the structural 
lipid of central nervous system gray matter [1], and must be supplied in especially large 
quantities for the brain growth spurt during perinatal development [2,3].  Long chain 
omega-3 and omega-6 fatty acids are also precursors for lipid mediators known as 
eicosanoids and docosanoids, which convey signals controlling inflammation and blood 
clotting, among many other physiological conditions [4].  Together with their fatty acid 
precursors, they also affect gene expression directly by interaction with nuclear 
receptors [5].  Although long-chain omega-3 and omega-6 fatty acids can be obtained 
directly from diet, genetic evidence suggests that biosynthesis is also important for 
optimal health throughout life.  Single nucleotide polymorphisms (SNPs) in FADS2 have 
been associated with allergy and atopic eczema, total cholesterol, LDL, C-reactive 
protein levels, and coronary artery disease risk, as well as cognitive outcomes such as 
attention-deficit hyperactivity disorder and IQ in children [6,7,8,9,10,11].   
 
Recently, we discovered that FADS2 is alternatively spliced to generate an alternative 
transcript (FADS2 AT1) with a pattern of expression that differs from the classical form 
in primate tissues [12] .  No function has yet been found for this alternative splice 
variant, but its expression is conserved across numerous species [13].  We have also 
identified 7 alternative transcripts for FADS3, an adjacent gene thought to encode a 
desaturase due to its sequence homology to other FADS (fatty acid desaturase,  
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Figure 4.1.  FADS2 codes for a desaturase that adds cis double bonds to the growing 
fatty acid chains in omega-3 (n-3) and omega-6 (n-6) long chain polyunsaturated fatty 
acid synthesis.  Nomenclature refers to the number of carbons and double bonds (e.g., 
20:5n-3 has 20 carbons and 5 double bonds, with n-3 describing distance of the double 
bonds from the terminal methyl carbon of the fatty acid.)  The end-products of the 
biosynthetic pathway give rise to eicosanoids and docosanoids with opposing effects.   
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referring specifically to the cluster of genes comprised of FADS1, FADS2, and FADS3) 
genes [14].  Although the function of FADS3 and its alternative splice variants is 
unknown, SNPs in this gene are associated with plasma sphingolipids, triglycerides, 
and myocardial infarction, and expression of FADS3 is altered in familial combined 
hyperlipidemia, and in mouse uterus at the site of embryo implantation [15,16,17].  
Although the genetic evidence suggests that FADS3 is important for lipid metabolism, 
mechanisms by which genetic variants in FADS3 affect blood lipids and disease have 
not been identified. 
 
Here, we investigated regulation of fatty acid desaturase alternative pre-mRNA splicing.  
Two major classes of splicing factors are known to function in opposing ways to 
regulate splicing: the serine-arginine (SR) proteins, which typically enhance splicing, 
and the heteronuclear riboprotein (hnRNP) family, known for splicing repression [18].  
Polypyrimidine tract binding protein (PTB, also known as PTBP1 or hnRNP I) is a 
member of the hnRNP family that usually acts as a repressor, but also sometimes 
enhances splicing, depending on the location it binds pre-mRNA and proximity to 
binding sites for other splicing factors [19].  The majority of PTB protein is normally 
found in the nucleus, but under some circumstances it can relocalize to the cytoplasm, 
where it affects mRNA stability and translational efficiency [20].  Although sometimes 
described as ubiquitous because it is expressed by most or all cell types at some point 
during development, PTB protein levels vary in different tissues, and control of function 
by phosphorylation allows for dynamic temporal and spatial adjustment of PTB activity.  
 
 PTB is known to be a primary regulator of alternative splicing for several genes [20], 
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and presumably affects numerous others.  However, relatively little is known about high-
level functional changes resulting from PTB activity.  PTB appears to promote growth in 
some cancer cell types [21], and it binds pyrimidine tracts in several growth-promoting 
genes, encouraging transcription [22].  Cytoplasmic PTB has been shown to enhance 
production of both insulin and insulin secretory granules by stabilizing mRNA, leading to 
increased translation [23].  These functions are consistent with switching from lipid 
utilization to glucose as an energy source, and enhancing fatty acid biosynthetic 
pathways, but to our knowledge PTB has never been directly linked with lipid 
metabolism.  
 
Preliminary bioinformatics predictions suggested that PTB might function in regulation of 
FADS2 alternative splicing.  To investigate this, we examined binding of PTB in vitro to 
a putative exonic silencer site, effects of PTB knockdown with siRNA, and expression of 
PTB relative to FADS alternative transcripts in baboon tissues.  Finally, we 
demonstrated changes in the ratio of omega-3 to omega-6 fatty acids with PTB 
knockdown in liver-derived cells.   
 
Materials and Methods 
 
Cell culture 
For all experiments, human HepG2 hepatocellular carcinoma and SK-N-SH 
neuroblastoma cells were maintained within ten passages of the original passage 
received from the ATCC.  HepG2 cells were grown in MEM with 10% FBS, and SK-N-
SH cells were grown in DMEM/F-12 with 10% FBS (media and serum obtained from 
HyClone) in a humidified environment at 37°C with 5% CO2.   
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In vitro RNA binding assay 
HepG2 nuclear extracts were prepared from cell lysates using the Qproteome Nuclear 
Protein Kit (Qiagen).  Protein concentration was determined using a BCA Protein Assay 
Kit (Pierce).  Biotin labeled RNA oligos (Integrated DNA Technologies) were suspended 
in nuclease-free PBS.  The sequences used were: FADS2wt 
GAUUAUGGCCACCUGUCUGUCUACAGAAAA, and FADS2mut 
GAUUAUGGACAGAGAUAGACGGACAGAAAA.  PTB binding to wild type (wt) but not 
to the mutant version was predicted using the online tool Splicing Rainbow (EMBL-EBI 
Alternative Splicing Workbench, <http://www.ebi.ac.uk/asd-srv/wb.cgi>) [24].  For each 
binding reaction, 1 mg of magnetic streptavidin-labeled M-280 Dynabeads (Invitrogen) 
were first pre-washed to remove nucleases, following the manufacturer’s recommended 
protocol.  Beads were mixed with 27 μg of biotin-RNA and 15 μg of nuclear extract in 
PBS for 30 minutes with gentle rotation at 4°C.  Beads were washed four times with 
PBS, then bound proteins were eluted with the addition of Laemmli sample buffer and 
boiling for 5 minutes.  Eluted proteins were loaded onto a Mini-Protean pre-cast Any KD 
SDS-PAGE gel (Bio-Rad) along with 15 μg nuclear extract as a positive control.  After 
separation, proteins were transferred to a nitrocellulose membrane (Li-Cor).  The 
membrane was probed with antibodies at the following dilutions: mouse SH54 anti-PTB 
(EMD), 1:100; rabbit anti-beta-actin (Li-Cor) as a negative control, 1:1000; goat anti-
mouse 680LT (Li-Cor), 1:10,000; goat anti-rabbit 800CW, 1:15,000.   The blot was 
visualized on a Li-Cor Odyssey two-color fluorescence imager. 
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siRNA 
PTB siRNA (100 nM) and control non-targeting siRNA (Dharmacon siGENOME 
SMARTpool) were used in triplicate treatments with Dharmafect 4 (HepG2) or 
Dharmafect 1 (SK-N-SH), following the manufacturer’s protocol. SMARTpool reagents 
contained four different siRNA, allowing lower concentrations of individual siRNA to be 
used in order to prevent off-target effects.  In addition, a combination of sense and 
antisense strand chemical modifications that reduce off-target effects were incorporated 
when needed [25].  Cells were treated for 72 hours before RNA or lipid extraction.  For 
fatty acid treatment, omega-3 docosapentaenoic acid (22:5n-3) was first non-covalently 
bound to fatty-acid free bovine serum albumin (BSA).  Fatty acid sodium salts were 
suspended in PBS, then mixed with fatty-acid free bovine serum albumin in a 3:1 ratio 
of fatty acid to albumin, and incubated for 5 hours at 37°C.  RNAi was carried out as 
usual, with the addition of 25 μM BSA-bound 22:5n-3 or vehicle (BSA only) in the media 
for the entire 72 hour incubation.    
 
RNA extraction and PCR 
Banked neonate baboon tissues were obtained in a previous study from our laboratory 
[26], and stored from time of necropsy at -80°C until RNA was extracted.  All tissues 
were from a 12-week old control animal that had been fed an infant formula containing 
no long chain PUFA.  Live baboon work was carried out at the Southwest Foundation 
for Biomedical Research (SFBR) in San Antonio, TX.  Animal protocols were approved 
by the SFBR and Cornell University Institutional Animal Care and Use Committee 
(IACUC, protocol # 02-105.)  Baboon tissue and cell culture RNA was extracted, RNA 
integrity assessed, cDNA prepared, and semi-quantitative RT-PCR carried out as 
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described previously [14].  PCR primers designed for FADS splice variants (Integrated 
DNA Technologies, sequences available upon request) were validated by cloning and 
sequencing PCR products.  Gel bands were analyzed by densitometry using ImageJ 
software (National Institutes of Health).  Quantitative real-time PCR was carried out 
using SYBR Green Master Mix (Roche) on a LightCycler 480 instrument (Roche), with 
β-actin chosen from a panel of candidate reference genes because it was not affected 
by cell treatments.  PCR reaction efficiency was calculated from standard curves, and 
reactions were assessed by both melting curves and by running on agarose gels to 
verify reaction products and the absence of primer-dimers.  Quantitative cycle (Cq) 
values were determined using LightCycler 480 SW1.5.0SP3 software, version 1.5.0.39 
(Roche).  Analysis was carried out with REST 2009 software (Qiagen), which employs 
the Pfaffl method for relative quantification [27], and uses bootstrapping and 
randomization techniques to calculate fold changes and statistical significance.  
 
Fatty acid analysis 
Cells were washed with HBSS, then trypsinized to remove from growth surfaces.  After 
centrifugation and removal of supernatant, lipid extraction was carried out on the cell 
pellets.  Fatty acid methyl esters (FAME) were prepared using a modification of the one-
step method of Garces and Mancha [28].  FAME were analyzed in triplicate and 
quantified by gas chromatography-flame ionization detection (GC-FID), using an equal 
weight FAME standard mixture to verify response factors daily [29].  Peak identities 
were confirmed by GC-covalent adduct chemical ionization tandem mass spectrometry 
(GC-CACI-MS/MS) [30,31,32].  The standard deviation for ratios (fold change in 
treated/control) was calculated using a propagation of error approach.   
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Results 
 
PTB is predicted to bind FADS2 and FADS3 exonic splice sites 
 
To identify putative binding sites for splicing factors that might regulate alternative 
splicing of FADS genes, we investigated alternative exonic splice sites in FADS2 (NCBI 
accession no. EU780003) and FADS3 (NCBI accession no. EU780002) using the 
bioinformatics tool Splicing Rainbow (EMBL-EBI Alternative Splicing Workbench, 
<http://www.ebi.ac.uk/asd-srv/wb.cgi>) [24].  The alternative transcripts (AT) and in vivo 
expression patterns of FADS2 and FADS3 splice variants have been described in detail 
previously [12,14].  Approximately 30nt regions flanking splice sites identified from our 
previous work were examined for predicted binding sites.  Numerous splicing enhancer 
binding sites were predicted, but there was also a striking pattern of predicted PTB 
binding directly on splice sites identified from baboon cDNA for FADS2 AT1 (NCBI 
accession no. FJ901343) and FADS3 AT7 (NCBI accession no. FJ641203).  The 
alternative splice site in FADS2 Exon 4 occurred at base 7 of the 14-mer predicted PTB 
binding site.  FADS3 Exon 8 included a 35 nt stretch predicted to bind PTB, with the 
alternative splice site located at nucleotide 19 of the 35-mer. Replacing the sequences 
with human cDNA sequences yielded identical binding predictions.  In addition, FADS3 
AT1 (NCBI accession no. EU780004) exhibited a predicted PTB binding site near the 
splice site, but not overlapping with it.   
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PTB is associated with the FADS2 alternative splice site in vitro 
 
To test the validity of the predicted binding sites, we carried out an in vitro RNA pull-
down assay to determine whether the putative exonic splicing silencer (ESS) in FADS2 
could pull down PTB from nuclear extracts.  Biotinylated RNA oligos were designed 
containing either the intact 14-mer human predicted binding site, or a mutated binding 
site of equal length, with pyrimidines in the binding site replaced by purines in the 
mutant, but retaining the same flanking sequences (oligo sequences shown in Materials 
and Methods section).   The mutant sequence was checked with Splicing Rainbow to 
ensure that no consensus binding sites for other splicing factors were introduced in the 
process of altering the predicted PTB binding site.  Each oligo was incubated with 
nuclear extract, and RNA-bound proteins were eluted and detected by Western blotting.  
Whole nuclear extract was run in parallel as a positive control, and the blot was probed 
for β-actin as a negative control to detect non-specific protein binding.  As shown in 
Figure 4.2, PTB bound preferentially to the predicted ESS rather than the mutant 
version.  
 
PTB knockdown upregulates FADS2 AT1 and FADS3 AT7 
 
Because PTB has previously been shown to repress splicing by sterically hindering 
binding of splicing enhancers [20], we hypothesized that PTB might function as a 
repressor for FADS2 AT1 and FADS3 AT7 expression.  To investigate this hypothesis, 
siRNA against PTB was used to knockdown PTB in human neuronal (SK-N-SH) and  
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Figure 4.2.  Western blot showing eluted proteins from an RNA pull-down assay (first 
two lanes) run in parallel with whole nuclear extract (NE) as a positive control.   PTB 
was pulled down by an RNA oligo containing the FADS2 putative binding site (wt), but 
not by a mutated version (mut), with no non-specific binding of β–actin.  
wt mut NE
PTB
β-actin
kDa
57
45
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liver-derived (HepG2) cells.  Expression of the alternative transcripts was examined by 
RT-PCR using primers designed to bridge sequences unique to each splice variant.  In 
a preliminary time course experiment, FADS2 AT1 levels rose with time, concomitant 
with reductions in PTB mRNA levels in SK-N-SH cells (Figure 4.3A).  Changes in 
expression were investigated in more detail in HepG2 cells with quantitative real-time 
PCR for transcripts in the FADS gene cluster (Figure 4.3B).  With > 90% knockdown of 
PTB, FADS2 AT1 expression increased 1.48 fold, while FADS3 AT7 increased 1.39 
fold, consistent with splicing repression by PTB.  Interestingly, FADS3 AT1 relative 
mRNA abundance decreased slightly, suggesting PTB might play a role in stabilizing 
splicing of this transcript.  There were no significant changes in FADS1, FADS2 
(classically spliced, CS), or any other FADS3 transcripts (data not shown).  The 
concentration of FADS2 AT1 is about 10-fold lower than FADS2 CS in HepG2 cells 
(estimated from Cq values for identical cDNA dilutions), so even a 50% increase in 
FADS2 AT1 levels would decrease FADS2 CS by only 5%, well below the detection 
limit for real-time PCR; hence no reduction in observed FADS2 CS is expected.  Thus, 
in this liver cell model, PTB knockdown was sufficient to regulate splicing of FADS2 AT1 
and FADS3 AT7 transcripts. 
 
PTB is inversely correlated with FADS2 AT1 in baboon tissues 
To understand the role of PTB in regulating tissue-specific splicing of FADS genes in 
vivo, we examined levels of FADS2 AT1, FADS3 AT7, FADS3 AT1, and PTB mRNA in 
neonatal baboon tissues.  Eight of 11 tissues evaluated followed an inverse correlation 
of FADS2 AT1 with PTB mRNA levels (Figure 4.4A, R2 = 0.87), suggesting that PTB  
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Figure 4.3.  (A) RT-PCR results for a time-course of PTB siRNA knockdown in SK-N-
SH neuroblastoma cells, showing increasing FADS2 AT1 (■) with decreasing PTB (□).  
Integrated densities of gel bands were normalized to actin and expressed as the ratio of 
knockdown/control. (B) Quantitative real-time PCR showing fold change in FADS gene 
transcript expression in HepG2 cells for PTB knockdown compared to non-targeting 
siRNA control, n=3 biological and technical replicates. * p < 0.01   
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Figure 4.4.   The combination of splicing and transcriptional regulation determines 
FADS2 AT1 levels in vivo.  (A) Splicing regulation is suggested by inverse correlation of 
PTB and FADS2 AT1 in the majority of neonatal baboon tissues examined (■), with R2 = 
0.87 for trend excluding tissues with low PTB (∆).  Axes represent RT-PCR integrated 
densities normalized to -actin.  (B) Tissues with low PTB levels (∆) closely follow the 
trendline relating FADS2 AT1 with FADS2 CS (R2 = 0.74 for trend including all points), 
suggesting transcription-level regulation (pre-mRNA abundance) is the primary 
determinant of FADS2 AT1 levels in the three tissues with low PTB.   
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may play an important role in regulating FADS2 tissue-specific splicing in vivo.  The 
three tissues with the lowest levels of PTB did not fit the pattern; these results are 
consistent with predominant transcription-level control in these tissues, since levels of 
FADS2 AT1 corresponded closely with FADS2 CS levels in tissues with relatively low 
PTB (Figure 4.4B).  Unlike FADS2 AT1, there was much lower correlation between PTB 
levels and FADS3 AT7 or FADS3 AT1 in baboon tissues (Figure 4.5).   There was a 
slight inverse correlation of PTB and FADS3 AT7 (Figure 4.5A, R2 = 0.44) in the same 
eight tissues examined above, while FADS3 AT1 showed very little correlation with PTB 
(Figure 4.5B, R2 = 0.26).   
 
PTB knockdown specifically decreases omega-3 fatty acid content 
To determine functional consequences of upregulation of FADS2 AT1 and FADS3 AT7, 
the fatty acid composition of HepG2 cells was analyzed after PTB knockdown or control 
siRNA treatment (Figure 4.6, gray bars).  Both omega-3 and omega-6 fatty acids 
decreased significantly after PTB knockdown, offset by a slight increase in 
monounsaturates and no change in saturated fatty acids.   Interestingly, in all cases, 
omega-3 fatty acids declined more than omega-6 fatty acids (23% decrease overall 
compared to 13%, respectively, p < 0.01 for the difference).  There was a 12% reduction 
(p = 0.005) in the ratio of total omega-3 to omega-6 fatty acids with PTB knockdown.   
 
The most dramatic change with PTB knockdown was a 50% reduction in 
eicosapentaenoic acid (EPA, 20:5n-3) content coinciding with upregulation of FADS2 
AT1 and FADS3 AT7.  Although both EPA and arachidonic acid (ARA, 20:4n-6) levels  
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Figure 4.5.  Lower correlation between PTB and FADS3 transcripts.  (A) Slight inverse 
correlation of FADS3 AT7 and PTB in the majority of neonatal baboon tissues examined 
(■), with R2 = 0.44 for trend excluding tissues with low PTB (∆).  Axes represent RT-
PCR integrated densities normalized to β-actin.  (B) Low correlation of FADS3 AT1 and 
PTB, with R2 = 0.26 for trend excluding tissues with low PTB (∆). 
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Figure 4.6. Fatty acid composition of liver-derived HepG2 cells, showing fold change in 
concentration of each fatty acid with PTB siRNA compared to non-targeting control 
siRNA.  Gray bars represent treatments in regular media, and black bars are media 
supplemented with 25 μM 22:5n-3.  All changes shown were significant at p < 0.05, 
except for 18:3n-6 in regular media.  (A) Omega-6 (n-6) fatty acids, (B) Omega-3 (n-3) 
fatty acids, (C) Summary of total fatty acids and ratios of fatty acids with opposing 
effects. 
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declined with PTB knockdown, EPA levels went down much more than ARA levels; the 
ratio of EPA/ARA was reduced by 43% (p = 0.0002) with PTB knockdown.   
 
 The EPA precursors 20:4n-3 and 18:3n-3, normally at very low levels in most cells, 
were below quantifiable limits, and thus the substrates were not accumulating as EPA 
product decreased.  However, the ratio of 20:3n-6 with its precursor, 18:3n-6, 
decreased 17% with PTB knockdown (p = 0.0005), consistent with inhibition of the 
elongation step from 18-carbon to 20-carbon polyunsaturated fatty acids.   
 
To determine how specific the inhibitory activity was for EPA synthesis compared to 
longer chain omega-3 fatty acids, we asked whether adding 22:5n-3, an elongation 
product of EPA, would rescue levels of the desaturation product 22:6n-3 
(docosahexaenoic acid, or DHA).  To investigate this, PTB knockdown was repeated in 
HepG2 cells in the presence of media supplemented with 22:5n-3 (Figure 4.6, black 
bars).  As before, EPA levels were sharply reduced with PTB knockdown, as was the 
ratio of EPA to ARA, and the ratio of total omega-3 to omega-6 fatty acids.   Despite 
22:5n-3 supplementation, levels of 22:5n-3, 22:6n-3, and the elongation product 24:6n-3 
were still significantly reduced with PTB knockdown, though the differences from control 
cells tended to be less obvious than without supplementation.  For example, 22:6n-3 
concentration declined 21% in PTB knockdown compared to control (p = 0.001) in 
unsupplemented cells, whereas the decrease was only 13% (p = 0.002) in cells 
supplemented with 22:5n-3.   Thus, the reduction in total omega-3 levels with PTB 
knockdown cannot be entirely explained by reduction in EPA, since 22:5n-3 
supplementation failed to completely rescue levels of downstream desaturation 
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products.    
 
Discussion 
 
Here, we have demonstrated that PTB plays a role in repressing expression of FADS 
splice variants and altering cellular omega-3 to omega-6 fatty acid ratio.  Knockdown of 
PTB in liver-derived cells led to upregulation of both FADS2 AT1 and FADS3 AT7, and 
an RNA pulldown assay showed that PTB was associated with the putative binding site 
in FADS2 in vitro.  Further studies are needed to determine whether PTB binds directly 
to the predicted binding site, or whether other proteins are necessary for PTB binding 
and splicing repression.  Our RNAi results showing roughly equivalent induction of 
FADS2 AT1 in liver and neuronal-derived cells, despite very different levels of PTB 
silencing, corroborate the idea of additional, tissue-specific factors contributing to 
splicing regulation in different cell types. However, the fact that the putative PTB binding 
sites overlap with the alternative splice sites in FADS2 and FADS3 strongly suggests 
PTB binding sterically hinders access of splicing machinery proteins to the splice sites.  
Moreover, the high correlation of the expression pattern of FADS2 and PTB in baboon 
tissues suggested that PTB alone may be an important regulator of FADS2 splicing in 
vivo.  FADS3 splicing was not as closely correlated with PTB mRNA levels in baboon 
tissues.  It is possible that post-transcriptional regulation of PTB is more important than 
mRNA level in determining splicing repression of FADS3.  There also are likely to be 
other important regulators of FADS3 splicing that vary by tissue type, and interact with 
PTB to determine the final splicing pattern.  Alternatively, the paralog PTBP2 may 
replace PTB in repressing FADS3 splicing in some tissues, since PTBP2 has some 
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functional redundancy with PTB [33].  However, the increase in FADS3 AT7 levels in 
HepG2 cells in response to PTB knockdown may reflect liver-specific regulation, where 
PTB alone may play a major role.  The 40-50% changes in expression we observed in 
vitro were relatively subtle compared to changes often observed in disease states, but 
similar fold changes have routinely produced important biochemical changes in studies 
of nutritional effects on metabolic genes [24,34,35,36]. 
 
Knockdown of PTB in liver-derived cells also resulted in decreased cellular omega-3 
and omega-6 fatty acid content.  Omega-3 fatty acids decreased by nearly one half 
relative to omega-6 fatty acids in PTB knockdown cells compared to controls.  These 
results were surprising because the same enzymes operate on both omega-3 and 
omega-6 fatty acids (Figure 4.1), so it has been accepted that synthesis of both occur 
largely in concert.  Intervention studies to raise the proportion of omega-3 relative to 
omega-6 fatty acids in cell membranes have always focused on dietary modifications, 
since it was presumed that consuming altered ratios of substrates or end-products was 
the only way to change cellular ratios of omega-3 to omega-6 fatty acids.  However, 
puzzling biochemical evidence has occasionally emerged suggesting the possibility of 
separate delta-6 desaturase enzymes for different fatty acids [37,38].  The idea of 
separate enzymes lost favor after the discovery of a single FADS2 gene, which was 
found to code for a desaturase with dual substrate activity toward both omega-3 and 
omega-6 fatty acids [39].  Since classical enzymes in the biosynthetic pathway accept 
both classes of fatty acids as substrates, it is difficult to explain how the omega-3 to 
omega-6 fatty acid ratio could change without any alteration in media components.   
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A reasonable alternative is that desaturase splice variants may be able to preferentially 
bind and sequester omega-3 fatty acid substrates and remove them from availability for 
enzymatic reactions, leading to a greater reduction in omega-3 than in omega-6 
content.  Our results provide only circumstantial evidence linking desaturase alternative 
splicing with fatty acid changes.  However, this hypothesized role for FADS splice 
variants is appealing because dominant negative inhibition is a common role for 
alternative splice variants; splicing can generate variants that are able to bind 
substrates, but do not contain domains necessary for enzymatic reactions [40].  FADS2 
AT1 lacks a conserved cytochrome b5 domain and the first histidine motif, and FADS3 
AT7 lacks the last histidine motif characteristic of front end desaturases [12].  Binding 
non-productively to substrates reduces the effective concentration of substrate available 
for reactions, and thus limits product formation in biosynthetic pathways.  Sequestration 
of fatty acids would affect both elongation and desaturation reactions, while also 
disrupting processes such as fatty acid incorporation into phospholipids.  The resulting 
change in omega-3 to omega-6 ratio alters cell membrane structure, and is known to 
influence function of rhodopsin, a G-protein coupled receptor [41], as well as changing 
physiological responses such as inflammation through the production of lipid mediators 
with opposing functions [5]. 
 
The desaturase splicing pattern resulting from PTB knockdown was associated with a 
particularly strong decrease in EPA concentration, and the ratio of EPA with ARA.  
Although EPA is present as only a small percentage of total fatty acids, it is a precursor 
to several families of bioactive eicosanoids, including prostaglandins, thromboxanes, 
and leukotrienes.  Products of EPA tend to act in direct opposition to eicosanoids 
  94 
derived from ARA; EPA-derived eicosanoids have anti-inflammatory, anti-arrhythmia, 
anti-coagulant, and pro-vasodilation effects [5]. Because levels of ARA in tissues tend to 
be tightly regulated [42], specific modulation of EPA may be an effective way to adjust 
ARA net activity without a large change in ARA concentration.  Moreover, because 
eicosanoids are paracrine species that function with high potency but very short half-life 
[43], a mechanism to specifically modulate EPA levels in different cell types would allow 
for flexible localized responses.  
 
The ratio of 20:3n-6 with its precursor, 18:3n-6, decreased significantly with PTB 
knockdown, suggesting that the elongation step from 18-carbon to 20-carbon 
polyunsaturated fatty acids is inhibited.  Sequestration of 18-carbon fatty acids by 
dominant negative desaturase splice variants, with a preference for omega-3 over 
omega-6, may be expected to decrease EPA levels by effectively suspending metabolic 
transformations, including acylation and recycling pathways.  This, in turn, would 
decrease levels of all longer-chain omega-3 fatty acids in the biosynthetic pathway, 
consistent with our observations.  However, the failure of 22:5n-3 supplementation to 
rescue levels of longer chain fatty acids in the pathway suggests binding affinity for both 
18-carbon and >20-carbon fatty acids, as is observed in functional FADS2CS [44].  
Long chain omega-3 products such as 22:6n-3 may also be important in mediating 
PTB’s high-level functions. 
  
Fatty acid composition is well known to change in many tissues and cells during 
development, as well as during disease states and nutrient deficiency conditions.  
However, the results reported here represent a rare demonstration of a mechanism 
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specifically altering the cellular omega-3 to omega-6 fatty acid ratio in well nourished 
cells without any change in diet/media, and the first associated with a splicing factor.  
Moreover, the sensitivity of PTB to extracellular stimuli and developmental stage 
provides a means to fine-tune cellular desaturase activity and the ratio of EPA to ARA, 
as needed for different tissue types or physiological states.  These findings reveal a 
novel role for PTB as a modulator of the availability of key membrane components and 
eicosanoid precursors, with the potential to propagate extracellular signals to affect the 
circulatory system and inflammatory responses.   
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CHAPTER 5 
CONCLUSION AND FUTURE DIRECTIONS 
 
The three studies presented here have in common an underlying theme of desaturase 
regulation.  Several facets of regulation were examined, from transcriptional control to 
mRNA splicing regulation, and from these a model of the overall effects on LCPUFA 
metabolism is beginning to emerge. 
 
In the first study, SNPs and a minor haplotype were associated with lower FADS1 
expression in the Japanese HapMap population.  We found two deletion mutations near 
a putative sterol response element in individuals carrying the minor haplotype.  This 
genotype was associated with greater response to desaturase transcription activation 
by SREBP-1c modulators, including a statin drug and an LXR agonist.  We have 
identified a locus in FADS2 intron 1 that appears to be a major bidirectional regulatory 
region affecting both FADS1 and FADS2 expression.  These results may provide a 
mechanism to explain other studies finding associations of SNPs in this region with 
diseases and other phenotypes.   
 
Further research is required to determine whether these deletion mutations cause the 
altered response to SREBP-1c, or if they are markers for a causal genetic variation that 
has yet to be found.  The reason for lower basal FADS1 also remains a mystery, but 
lower desaturase expression implies that individuals with this genotype would be 
especially good candidates for recommendations of increased fish consumption or 
supplementation with marine oils.  It would also be of interest to establish the 
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prevalence of these variants in other populations besides the Japanese, particularly in 
European-derived populations that derive major benefits from statin use.  The discovery 
of this genetic association provides an opportunity to study the extent to which induction 
of LCPUFA mediates the medical benefits of statin drugs.  Namely, do people carrying 
these deletions have reduced cardiac mortality on statin drugs compared to others on 
statins?   
 
Several other chemical entities are known to affect desaturase activity by modulating 
SREBP-1c, and these are likely to show differences by genotype similar to those 
observed for the statin and LXR agonist.  These include the top-selling antipsychotic 
drugs, but it is unclear whether LCPUFA contribute to the medical benefits of these 
drugs.  Similarly, insulin has recently been shown to activate SREBP-1c [1], suggesting 
that the induction of desaturases by insulin may occur via this mechanism, and may 
show individual differences by genotype.  It would also be of great interest to know how 
dietary cholesterol affects LCPUFA levels in individuals carrying these deletions, and 
whether differences in dietary cholesterol could explain the genetic associations of 
nearby SNPs with IQ in studies comparing formula fed with breastfed children.  The 
exclusion of cholesterol from infant formula, despite evidence that it is universally 
present in breast milk, has long been controversial, and our results may cause this 
argument to be revisited.   As we demonstrate here, LCPUFA (present in breast milk 
and in most modern formula products) downregulate FADS1 and FADS2, but 
cholesterol (in breast milk only) in theory counteracts this effect through SREBP-1c. 
 
The second study addressed regulation of the putative desaturase, FADS3.  We found 
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that infant formula containing LCPUFA upregulated several FADS3 alternative 
transcripts while downregulating FADS1 and FADS2 in infant baboon liver.  
Reproducing the effect in liver-derived cells showed that LCPUFA act directly rather 
than via an endocrine response, and that the mechanism involves PPARgamma.  
These results, showing an opposite pattern of regulation and different mechanism for 
response to LCPUFA, suggested that FADS3 and/or its splice variants had a unique 
function rather than being similar to FADS1 and FADS2.  
 
We explored this idea further in the third study, examining the role of PTB in repressing 
alternative mRNA splicing of FADS2 and FADS3.  PTB knockdown upregulated FADS2 
AT1 and FADS3 AT7 and specifically decreased the n-3/n-6 ratio in liver-derived cells.  
There was an especially dramatic decrease in levels of EPA relative to ARA, suggesting 
that fatty acid changes in response to PTB activity might impact eicosanoid levels, 
affecting inflammation and blood clotting, among other processes.  These results 
suggested that these splice variants might act as dominant negative inhibitors of 
classical desaturases.   
 
The hypothesis of dominant negative inhibition by splice variants is also consistent with 
our results showing upregulation of FADS3 AT in response to LCPUFA.  Cells decrease 
desaturase expression in response to LCPUFA as a mechanism of feedback inhibition, 
preventing excessive desaturation of cellular lipids.  Simultaneous upregulation of 
inhibitors of LCPUFA biosynthesis would be an efficient way to slow down biosynthesis 
without waiting for protein turnover to decrease desaturase levels.  Our results suggest 
splice variants have specificity for preferred fatty acids (implied by the greater decrease 
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in n-3 compared to n-6 fatty acids), which might explain why we have observed so many 
different alternative transcripts for FADS3.   
 
Feedback loops may also be relevant to function of PTB as a modulator of fatty acid 
composition.  Splicing activity of PTB can change in response to extracellular stimuli [2].  
Signaling cascades leading to PTB phosphorylation can change PTB subcellular 
localization [3]; redistribution of PTB out of the nucleus and into cytoplasm would be 
expected to replicate the effects of PTB knockdown on desaturase alternative splicing, 
and possibly cellular fatty acid composition.  It has been reported that PTB binding to 
inducible nitric oxide synthase mRNA can be modulated by cytokine stimulation [4], 
suggesting the intriguing possibility that the effect of PTB on eicosanoid precursor 
concentrations could be part of a positive or negative feedback loop responding to 
extracellular inflammation.  In addition, very preliminary evidence in our lab suggests 
that insulin treatment replicates the effect of PTB knockdown on FADS AT expression in 
HepG2 cells.  Cytoplasmic PTB is known to enhance production of both insulin and 
insulin secretory granules [5]; if our results can be replicated in pancreatic cells, insulin 
might stimulate redistribution of PTB out of nucleus and into cytoplasm, in a positive 
feedback loop promoting more insulin secretion. 
 
The studies reported here suggest that exquisite temporal and spatial control of 
LCPUFA production is achieved through a combination of transcriptional and splicing 
regulation of FADS genes.  Far from being a static or constitutive process, regulation of 
LCPUFA biosynthesis may be much more dynamic and responsive to external cues 
than previously thought.  Our genetic evidence further underscores the importance of 
  105 
regulation, suggesting that dysregulation of expression, rather than faulty enzyme 
structure, may underlie associations of FADS2 SNPs with diseases.  Understanding 
mechanisms for dietary, hormonal, and pharmacological regulation of fatty acid 
desaturases may improve our ability to treat or prevent diseases, and brings us another 
step closer to personalized medicine and individually-tailored dietary recommendations.   
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